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ABSTRACT. 
 
The utilization of high-throughput -omics strategies, such as proteomics, in the analysis of breast 
cancer will function to define central molecular characteristics across a disease that is associated 
with a high degree of molecular heterogeneity. Data reported herein details the investigation of 
key subjects in breast cancer biology focused on the characterization of endogenous and 
experimentally-induced disease biology characteristics utilizing the application of LC-MS based 
proteomic analyses of both in vitro models of breast cancer as well as primary clinical samples. 
Results include a combined global and functional proteomic strategy to identify governing 
functional roles for mutually, differentially abundant proteins observed across three divergent 
cell line models of breast cancer. Further, evidence is presented which provides insights into the 
regulatory activity of the breast cancer-associated microRNA (miR-145) in several cell line 
models of breast cancer in which expression of this microRNA has been restored. Lastly, robust 
analyses are detailed focused on the identification of differential protein characteristics indicative 
of disease stage as well as of recurrent disease in breast cancer derived from proteomic analysis 
of formalin-fixed, paraffin embedded (FFPE) clinical samples. These studies contribute to the 
field of proteomics in the form of 1) providing robust experimental workflows directed towards 
investigation of functional themes and associated functional targets in large protein data sets 2) 
detailing strategies for navigating the application of proteomic analysis to microRNA target 
discovery and 3) further development and utilization of methodologies towards the proteomic 
analysis of clinical, FFPE tissue samples. Furthermore, these studies benefit the breast cancer 
community on several fronts including 1) the elucidation of provocative protein candidates 
which warrant further investigation for their role in regulating disease mechanisms underlying 
 v 
breast cancer biology and 2) through the discovery of diagnostic markers indicative of discrete 
subtypes and stages of disease progression in breast cancer. The results reported herein detail 
disease-specific protein abundance characteristics associated with neoplastic progression in 
breast cancer that will benefit further expansion of the basic biological understanding of this 
disease and describes novel proteins for further evaluation as biomarker candidates for the 
diagnosis of breast cancer. 
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1.0 INTRODUCTION 
1.1: Breast Cancer - Background 
  
Breast cancer is the second leading cause of cancer related death in North American women, 
with greater than 200,000 new cases diagnosed and ~40,000 deaths estimated to occur in the US 
in 2010.1 The onset of breast cancer can occur as a product of genetic pre-disposition or 
sporadically and is associated with a variety of risk factors that include smoking, obesity, post-
menopausal hormone replacement therapy as well as evidence of increased breast density upon 
mammographic examination.2, 3 Inherited forms of breast cancer are commonly associated with 
germline mutations in key tumor suppressor genes, such as the canonical tumor suppressors 
tumor protein 53 (p53) and the phosphatase and tensin homolog (PTEN) as well as in the DNA 
damage sensors breast cancer, early onset 1 or 2 (BRCA1 or BRCA2), with mutations in this 
latter subset of genes increasing breast cancer risk by as much as 10-20%. 3, 4 Sporadic breast 
cancers can similarly occur due to tumor suppressor gene inactivation as well as due to 
overexpression of various oncogenes, such as the cell cycle regulatory factor cyclin D1, the 
proto-oncogene c-myc or the epidermal growth factor receptors ERBB1 (EGFR) or ERBB2 
(HER2/neu).3, 5 These genetic alterations underlie the basis of mammary epithelial cell 
transformation, with the acquisition of further genetic instabilities as nascent tumor cell 
populations expand, resulting in the production of tumor cells which display more aggressive 
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characteristics, such as those capable of localized invasion into adjacent breast tissues and 
metastasis to distal sites (Figure 2).5-7  
The adult human mammary gland is organized into 
systems of ductal structures which bridge lobular 
units, the sites of milk production, and the nipple, 
functioning as conduits for the transport of milk and 
nutrients (Figure 1).8   Ductal structures are lined by 
epithelial cells that face the luminal space of the duct, 
termed luminal epithelium, and are further enveloped 
by myoepithelial cells that interface with an adjoining 
basement membrane (BM), a protein-rich structure 
separating the mammary epithelium from adjacent 
connective, or stromal tissues (Figures 1 & 2).5, 8 
Mammary gland tissue maturation and functional 
activities are predominantly regulated by the cyclical 
modulation of two steroid hormones, estrogen and 
progesterone, that drive the growth and differentiation of these tissues.8 These steroid hormones 
bind to discrete nuclear hormone receptors, estrogen (ER) and progesterone (PR) receptors, 
resulting in nuclear translocation and binding of hormone receptor complexes to ER/PR 
promoter response elements in target genes resulting in their transcriptional activation.7 Breast 
cancer arises as a product of cellular transformation which is characterized by a series of discrete 
phenotypic changes that occur in mammary cells and include a failure to respond to growth 
inhibitory cues resulting in increased proliferative capacity and cell survival.9, 10 Transformed 
Figure 1. Anatomy of the Breast.
(A) – Ducts, (B) – Lobules, (C) –
Milk engorged duct, (D) – Nipple,
(E) – Fat, (F) – Pectoralis muscle,
(G) – Chest wall, (A1) – Ductal
epithelium. (B1) – Basement
membrane. (C1) – Ductal Lumen.
(Adapted from
http://www.breastcancer.org)
1
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mammary cells commonly originate from luminal epithelial cell types, less so from 
myoepithelial cells and further, recent evidence has revealed these populations may also arise 
from stem-cell like mammary progenitor cells. (Figure 2, normal duct panel).5, 11-14 The majority 
of breast cancers begin as premalignant lesions comprised of populations of hyperplastic 
epithelial cells that are confined to the intraductal space, termed atypical ductal hyperplasia 
(ADH). These lesions then progress to more aggressive localized disease, termed ductal 
carcinoma in situ (DCIS), the most common subtype of in situ disease, typified by increases in 
cell abundance and the acquisition of more aberrant cell morphologies being displayed by 
hyperplastic populations.6, 15 Disease progresses by invasion of tumor cells into adjacent tissues 
through degradation of the BM, a subsequent phase in progression of DCIS termed invasive, or 
infiltrating, ductal carcinoma (IDC) (Figure 2, in situ and invasive panels).5, 6, 11, 12, 16 The BM is 
predominantly comprised of large macromolecular complexes that include extracellular matrix 
Figure 2. Neoplastic Progression of Breast Cancer: Figure details a cross-sction
of the breast ductal epithelium and the progression from nascent through metastatic
disease. (Adapted from Polyak, K. 2007)
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(ECM) proteins, such as collagens, laminins and fibronectin which are actively secreted by both 
epithelial as well as stromal fibroblast cells.6, 11, 12, 16 Normal mammary epithelial cell survival is 
dependent upon interactions with the BM as these contacts provide anti-apoptotic and survival 
cues and is an event termed anchorage-dependence.11, 16, 17 Conversely, mammary tumor cells are 
capable of surviving in the absence of these interactions, so-called anchorage-independence, 
which is a phenotypic hallmark of cellular transformation.11, 16, 17  Degradation of the BM by 
tumor cells is achieved through modulation of ECM protein expression and interactions and as 
well as due to the aberrant expression and activity of various cellular proteases, such as the 
matrix metalloproteinase (MMP) family of endopeptidases.11, 16, 18 Invasion is further 
accompanied by disorganization and decreases in myoepithelial cell populations and increased 
numbers and activation of both stromal and immune cell types, precipitating an increase in 
growth factor and cytokine secretion, including the growth regulatory protein tumor growth 
factor beta (TGF-β) and the pro-angiogenic protein platelet-derived growth factor (PDGF). 5, 16, 18 
This cellular context produces a microenvironment that further drives tumor progression through 
enhancement of cellular signaling which supports pro-growth and invasive cellular behaviors, 
such as the conversion of epithelial tumor cells to mesenchymal-like cell types (EMT)19, which 
embodies tumor cells that exhibit more aggressive invasive potential.5, 16, 18 The evolution of 
tumor cells within this microenvironment results in the formation of hypoxic and acidic 
conditions due to restricted access to vasculature and a greater dependence of tumor cells on 
glycolysis versus oxidative metabolism for ATP production, a metabolic pathway which results 
in the conversion of pyruvate to lactate and lactic acid.20-22 These selective pressures promote 
activation of cell survival and angiogenic signaling resulting in locoregional invasion of tumor 
cells into adjacent lymphovascular tissues, such as to axillary or sentinel lymph nodes (SLN) 
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surrounding the breast, ultimately leading to the formation of metastasis which are distal from 
the primary tumor site, commonly occurring in the bones, lungs and livers of breast cancer 
patients. 11, 23 
 
The inherent genetic instabilities of mammary tumor cell populations and the dynamic 
microenvironments and selective pressures encountered by these cells in situ during neoplastic 
progression produces disease which exhibits high inter- and intra-patient molecular 
heterogeneity. These characteristics thus confound disease classification, prediction of disease 
prognosis and definition of optimal patient treatment options.24-28 The variety of disease 
etiologies and variability in therapeutic responses encountered in the treatment of breast cancer 
during the pre-genomic era underscored the basis for this disease to be one of the first solid 
Breast Cancer Subtype Receptor Status (Characteristics)
Luminal A ER+/ PR+/ HER2-(High ER levels)
Luminal B
ER+/ PR+/ HER2 (+/-)
(Lower ER, Higher PR)
(Luminal C? – ER+/PR+/HER2+) 
HER2+ ER-/ PR-/ HER2+(High HER2 levels)
Basal-like 
(Triple-negative) ER-/ PR-/ HER2-
Normal-Like Low expression of luminal-type genes, high expression of basal-epithelial genes. 
Table 1. Molecular Subtypes of Breast Cancer – Hormone receptor
and growth factor status. ER – Estrogen Receptor, PR – Progesterone
Receptor, ERBB2/HER2 (Human Epidermal growth factor Receptor 2)
23, 26, 28-31
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tumor cancers to be analyzed by global gene expression profiling utilizing complimentary DNA 
(cDNA) microarray analyses. 25, 26, 28, 29 Seminal studies published by Perou et al. 25 
encompassing microarray analyses of 85 tissue samples from 42 breast cancer patients as well as 
cell line models of normal and cancerous breast cells resulted in the identification of 5 
predominant molecular subtypes of breast cancer (Table 1).25, 28, 30-33 These subtypes indicated 
that key molecular signatures are conserved amongst breast cancers which bear specific hormone 
and growth factor receptor expression profiles, i.e. expression of ER and PR and the human 
epidermal growth factor 2 receptor (HER2). 25, 28, 30-33 Assessment of hormone receptor and 
HER2 expression status has been a facet of pathological analyses of breast cancer for over 20 
years and is typically achieved by immunohistochemical (IHC) analysis of biopsied patient tissue 
sections.27, 34-36 Of the five subtypes detailed in Table 1, three predominant subtypes are 
encountered clinically 1) the luminal subtype which is based on ER positivity, with the further 
sub-classification of luminal subtypes which are also HER2+ as being either luminal-b or 
luminal-c as currently being in debate by the community 33, 37, 2) HER2+ or 3) basal-like disease 
(Table 1).31, 32, 38 The majority of breast cancers diagnosed are of the luminal subtype, ~70%, and 
are associated with significantly better 5-year survival rates than the less commonly diagnosed 
HER2+ or basal-like subtypes.26, 39 In addition to insights into disease prognosis, assessment of 
hormone and growth factor receptor expression can further guide the selection of patient 
treatment options.31 Examples include the treatment of luminal breast cancers with estrogen 
receptor-specific antagonists, or selective estrogen receptor modulators (SERMS), such as 
Tamoxifen, as well as usage of a monoclonal antibody-based therapeutic, Trastazumab/ 
Herceptin, which is a  HER2 growth factor receptor antagonist used in the treatment of HER2+ 
disease.31 
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In conjunction with assessment of hormone and growth factor receptor status, a variety of 
clinicopathological analyses are utilized for the classification and determination of disease 
prognosis following an initial diagnosis of breast cancer. These include focused imaging studies, 
such as supplemental mammography with application of Breast Imaging Reporting and Data 
System (BI-RADS) assessment criteria, which provides insights into the likelihood that a 
mammographic finding may be normal, benign or malignant, as well as pathological analysis of 
patient tissue biopsies obtained by fine-needle aspiration cytology, stereotactic core needle 
biopsy or during surgical intervention.40, 41 Aside from determination of hormone receptor and 
HER2+ status, standard pathological analyses performed in breast cancer commonly encompass 
determination of disease stage as well as tumor grade.42-44 The criteria for staging breast cancer is 
summarized by the tumor node metastasis (or TNM) classification system that encompasses 
staging designations ranging from evidence of a carcinoma in situ lacking lymph node or distal 
metastasis, i.e. stage 0 disease, to the presence of tumor with nodal involvement as well as 
evidence of distal metastasis, i.e. stage IV disease.44 Determination of tumor grade (commonly 
the Nottingham grading system in the US), encompasses measures of mitotic rate, tubule 
formation, as well as the prevalence of nuclear polymorphisms in tumor cells.42, 43 Less common 
pathological analyses utilized for disease prognostication include assessment of the tumor 
proliferation index, which is commonly achieved via Ki-67 expression profiling, as well as by 
profiling for specific cytokeratins, such as CK5, CK14 and CK17 and for other growth factor 
receptors, such as human epidermal growth factor 1, or EGFR/ERBB1, which is often performed 
in basal-like breast cancer subtypes.45 These clinicopathological measures, with particular 
emphasis on the expression status of key hormone and growth factor receptors, comprise the 
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standard of care for breast cancer diagnosis and determination of disease prognosis.35, 46 Thus, as 
measures of hormone and growth factor receptor panels are core techniques utilized in the 
clinicopathological diagnosis of breast cancer, “proteomic” analyses have thus been a long-
standing facet of this field. 
 
1.2: Proteomics - Background 
 
Proteomics is defined as the study of global protein expression produced by a genome, cell, 
tissue or organism.47 This strategy is directed towards the high-throughput characterization of the 
full complement of protein species present within a complex protein mixture, enabling protein 
identification, the quantitation of protein abundance as well as characterization of post-
translational modifications (PTM) of proteins, such as phosphorylation and ubiquitination 
status.48-51 Early proteomic methods included two-dimensional gel electrophoresis (2-DE) which 
commonly entail separating a complex protein mixture by 1-D sodium dodecyl sulfate (SDS) 
polyacrylamide gel electrophoresis (PAGE) followed by further separation by isoelectric 
focusing (IEF), resulting in dissemination of heterogeneous protein populations occupying 
similar molecular weights into discrete protein groups.52 When comparing two conditions after 
staining, differential spot intensities provided relative quantitative information about protein 
abundance, and further mobility shifts in protein spots indicated the possibility of differential 
protein modifications between conditions.52 However, protein spot identification was typically 
achieved by direct sequencing of proteins, such as via N-terminal Edman degradation, a method 
which has since been largely displaced by mass spectrometry-based strategies. 52, 53  
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Proteomic strategies which utilize mass spectrometry and the application of so-called “shotgun” 
strategies directed towards the characterization of many proteins in a complex mixture, in 
Figure 3. Liquid Chromatography-Mass Spectrometry (LC-MS), Shotgun 
Proteomics Workflow – Sample preparation entails cell or tissue lysis followed by 
protein digestion, such as with the proteolytic enzyme trypsin. Resulting peptides are then 
separated into a less complex mixture by liquid chromatography and are ionized via 
electrospray ionization, resulting in evaporation of mobile phase and liberation of charged 
peptide ions. Peptide ions are then introduced into a mass spectrometer resulting in initial 
measurement of their intact mass to charge ratio (m/z), hypothetical peptide F-R-I-D-A-Y 
displayed in MS event, followed by a second, tandem MS event (MS/MS) in which an 
isolated peptide is fragmented by collision with Nobel gas molecules (termed collision 
induced dissociation (CID) followed by measurement of subsequent fragment ion m/z 
ratios.  
cellular isolation
Electrospray ionization (ESI)
F R I D
A
Y
Mass Spectrometry (MS)
F R
F R I
F
R
I
D
F
R
I
D
A
Tandem Mass Spectrometry (MS/MS)
Sample Preparation Protein Digestion Peptide Separation (LC)
10 
conjunction with various upstream fractionation methodologies, such as liquid-chromatography, 
i.e. LC-MS, enable more comprehensive characterization of proteins samples.49, 54 LC-MS-based 
proteomics (Figure 3 – ESI LC-MS/MS workflow) describes a strategy in which a complex 
protein mixture is enzymatically digested into constituent peptides which are then resolved 
utilizing liquid chromatography. This is achieved by binding of peptides onto an analytical LC 
column packed with a stationary phase in which peptides directly bind, such as reversed- phase, 
e.g. C-18 bonded silica beads, or ion exchange resins, such as strong-cation exchange.54 Peptides 
are progressively eluted via introduction of an increasing gradient of non-polar mobile phase, 
such as in the case of reverse-phase resins, over a defined period of time and eluted peptides are 
then introduced into a mass spectrometer via electrospray ionization (ESI) (Figure 3).51, 55,56 ESI 
entails the application of an ambient voltage to an analytical LC column resulting in the 
vaporization of eluting peptide droplets followed by transfer of subsequent gas-phase peptide 
ions into an MS source which is further under vacuum. 51 Intact peptide ion precursor m/z and 
CID spectra are then compared computationally to an in silico digested peptide library 
constructed from a species-specific protein database where CID spectra are scored based on their 
degree of concordance with predicted peptide masses and associated theoretical fragment ions 
masses. The highest scoring comparisons result in the identification of a peptide sequence 
followed by assignment of that peptide to a corresponding parent protein.57-59 Peptide 
identification accuracy is dependent upon the ability of a mass spectrometer to resolve unique 
peptide ion spectra, which aids in the determination of peptide charge state, and to perform 
highly accurate mass measurements of peptide precursors and fragment ions, which affords the 
application of more stringent criteria in peptide searches, thus, assuring more confident peptide 
identifications are obtained.51 Examples of high resolution, high mass accuracy mass 
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spectrometers include the Fourier transform-mass spectrometer (FT-MS) as well the Orbitrap 
MS which are capable of achieving resolutions in excess of 100,000 and mass accuracies of < 2 
parts per million (ppm). Lower resolution instruments include ion trap or TOF instruments which 
achieve average resolutions of 4.0-8.0 X 103 and mass accuracies >100ppm.51, 60 The application 
of further search criteria specifying peptide characteristics that are imposed by experimental 
design, such as the expectation that peptides generated by digestion of proteins with trypsin, a 
proteolytic enzyme which cleaves peptides bonds after lysine or arginine residues, will terminate 
in K or R, further aids to strengthen the validity of peptide identifications observed.61, 62 
Assembly of peptide identifications indicates the degree of protein coverage observed, with the 
general consensus in the proteomics community of a protein being identified by at least two 
peptides as being considered a confident identification.63 
 
Bottom-up, shotgun proteomic strategies, in which peptides produced by protein digestion are 
analyzed by LC-MS and then compiled to identify corresponding parent proteins, facilitates the 
identification and quantitation of many peptides/ protein species within a given sample. 48, 54, 64 
Comparisons of peptide identification rates (or spectral counts), peptide ion peak areas and 
intensities (such as in SILAC-analysis) or the peak intensities of fragmentation spectra derived 
from chemical tags covalently added to peptide species prior to MS analysis (such as in iTRAQ-
technologies), facilitates the quantitative comparison of global peptide species and thus protein 
abundance between multiple experimental conditions.65-67 Like other non-MS based protein 
abundance quantitation strategies, such as western and enzyme-linked immune absorbent assay 
(ELISA) analyses, comparative, quantitative analyses utilizing LC-MS-based proteomics begins 
with equivalent amounts of protein/ peptide concentrations. Spectral count-based quantitative 
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proteome analyses is achieved by comparison of equivalent peptide populations from multiple 
conditions where total numbers of peptides identified for a given protein are quantitatively 
compared across analyses to achieve a measure of differential protein abundance, where a greater 
number of peptides identified for a protein in sample 1 versus 2 would indicate relatively greater 
abundance in sample 1.65 To minimize the contribution of analytical variability imposed by 
differential sample processing or instrument performance, LC-MS analysis of isotopically-
labeled (SILAC) or chemically-tagged peptides (iTRAQ) affords the analysis of multiple 
experimental conditions simultaneously.66 67 For example, the SILAC MS approach affords 
concurrent analysis of up to three different complex protein mixtures as a product of metabolic 
labeling of proteins with either single or multiple amino acids that are labeled with stable isotope 
atoms (13C, 2H, 15N, or 18O) or ‘light’ (12C, etc.), being achieved via supplementation in tissue 
culture media in vitro or by dietary supplementation in in vivo animal studies.66 The result of 
metabolic labeling utilizing ‘heavy’ isotope amino acids is their incorporation into proteins that 
are identical to those from native conditions in all respects with the exception that they possess a 
greater mass according to the number of ‘heavy’ labeled amino acids present in the sequence.66 
Differentially labeled peptide populations are mixed in equivalent ratios and subjected to LC-
MS/MS in which peak areas for identical peptide isotopomers, which exhibit identical LC 
retention times differing only by the mass deflections contributed by the stable isotope-labeled 
amino acids, are thus compared providing quantitative information about the abundances of a 
given peptide/ protein across multiple conditions in a single LC-MS analysis.66, 68 
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Figure 4: Dynamic range of mRNA and protein abundance in cDNA versus LC-MS 
proteomic analyses: The dynamic range of expressed cellular genes and proteins vary 
from those ubiquitously expressed (such as structural/housekeeping factors) to factors 
present at lower abundances (such as kinases, transcription factors). As LC-MS, global 
proteomic analyses depends on de novo peptide/protein identification versus more targeted 
approaches utilized in gene expression / cDNA microarray analyses, the dynamic range of 
proteins poses a challenge to the comprehensive analysis of the full complement of 
proteins present in a cell lysate. The integration of further peptide/protein fractionation 
strategies paired with advances in MS instrument performance have benefited this 
analytical hurdle.  GAPDH: Glyceraldehyde 3-phosphate dehydrogenase, Glut-1: glucose 
transporter 1, MAPK: mitogen-activated protein kinase, p53: tumor protein 53, c-jun: AP-
1 early response transcription factor subunit. 
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The application of proteomic analyses to assess global protein abundance characteristics 
provides insights into the biology at play in a given tissue sample or cell population as it is a 
measure of the end-product of epigenetic, post-transcriptional and post-translational regulatory 
events.69, 70 However, the complexity and expansive dynamic range of the cellular proteome 
poses a challenge to the characterization of the full complement of proteins in a complex sample 
by proteomic analysis as this technique depends on the de novo characterization of proteins and 
peptides. This is in contrast to global gene expression profiling, such as cDNA microarray 
analyses, which affords greater specificity comparatively as observations are derived from the 
interaction of cDNA with pre-determined targets (Figure 4).71 Specifically, peptides 
corresponding to cellular proteins which are in high abundance, such as cytoskeletal or so-called 
“housekeeping” proteins, are over-represented in population of peptides derived from a total 
cellular proteome digest relative to peptides derived from more low abundant proteins, such as 
those which are often of interest in disease-related biological processes, e.g. protein kinases or 
transcription factors. Strategies to decrease the complexity of the cellular proteome prior to MS 
analysis have proven useful in achieving greater depths of proteome coverage, such as the 
application of in-gel digestion, involving separation of a complex protein sample by 1D SDS-
PAGE followed by dissection of gel spots containing protein populations at differing molecular 
weights and subsequent digestion and extraction of peptides. Further strategies which combine 
multiple orthogonal fractionation techniques, such as the multidimensional protein identification 
technology (or MudPIT) strategy, comprising an in-line LC technique which separates peptides 
firstly by strong cation exchange and then by reverse-phase chromatography have also increased 
proteome coverage.72 53 Further, advances in MS instrumentation, such as the recent release of 
the Velos series of mass spectrometers by Thermo Scientific, have resulted in technological 
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capabilities that have increased peptide identification rates by as much as 128% over previous 
technologies.73 With these strategies in place, protein identification capabilities and the high 
throughput nature of modern proteomic workflows have proven fruitful for the purposes of 
discovering biomarkers and elucidating functional biological roles of protein groups in a variety 
of disease-related pathologies including breast cancer. 
 
1.3: Proteomics of Breast Cancer – Biomarker Discovery 
 
The molecular heterogeneity of breast cancer underscores the benefits to be gained from analysis 
of this disease utilizing high-throughput gene and protein expression profiling. The main focus of 
these studies is to discover gene and protein expression characteristics that are conserved across 
breast cancer with the goal of identifying biomarkers which will aid in disease diagnosis by 
better defining disease subtypes and responsiveness to therapeutics as well as towards identifying 
systems of genes and proteins that underlie and drive breast cancer disease biology.74-76 The 
advantages afforded by proteomic analyses are that the targets of these studies are the 
predominant functional mediators of biology, which readily facilitates translation of identified 
proteins of interest to subsequent investigations towards discerning the utility of these candidates 
as therapeutic targets or as factors central to molecular disease mechanisms.74 Protein 
identification is the end product of post-transcriptional regulatory events which are mechanisms 
that can impact the translation of a gene target of interest; a lesson recently underscored by 
evidence which has emerged from the burgeoning field of microRNA-mediated regulation of 
gene translation.77-79 This point further underscores the value of performing multi-platform -
omics analyses of breast cancer in which genomic, differential mRNA, microRNA as well as 
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protein abundance characteristics are integrated at a systems level to provide insights into the 
regulatory dynamics underlying the gain or loss of factors associated with disease biology.80, 81  
 
As a product of the variety of sample types suited to proteomic analyses, such as the ability to 
analyze clinical tissue samples and biofluids as well as to perform high-throughput analyses of 
large sample sets, proteomic research in breast cancer has been largely directed towards the 
discovery of disease-specific protein characteristics that can be directly translated to clinical and 
therapeutic applications.74 The identification of biomarkers in breast cancer via proteomics has 
been approached utilizing models systems ranging from cell lines69, 82-91, animal models of breast 
cancer, including transgenic murine models bearing HER2 gain-of-function characteristics 92 and 
xenograft models of human breast cancer93-96, as well as in clinical samples ranging from blood 
serum97-102, cerebrospinal fluid (CSF)103 and nipple aspirate fluid (NAF)104-114 to clinical breast 
cancer tissues115-118 and breast cancer tissue effluent, or breast tissue interstitial fluid (TIF) 119-121.  
 
Investigations of breast cancer-specific protein abundance characteristics derived from studies of 
cell line models of breast cancer, in vivo breast cancer tissue models and clinical tissue samples 
have been driven by the logic that these sample sources will possess the most robust molecular 
characteristics representative of breast cancer disease biology. For example, a global, proteomic 
analysis utilizing a MALDI-TOF MS/MS approach of pooled membrane proteins derived from 
several human cell line models of breast cancer, namely the ER+ cell lines, MCF7 and T-47D, as 
well as the EGFR-positive cell lines MDA-MB-468 and BT-474, resulted in the identification of 
three novel proteins, i.e. BCMP11, BCMP84 and BCMP101. These proteins were found to be 
specific for cancerous versus normal breast epithelium in subsequent large cohort IHC analyses; 
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with BCMP11 in particular as being observed at high abundances in 43 versus 58 breast cancer 
patients analyzed.82 Further, recent analysis of an isogenic model of breast cancer disease 
progression, termed MCF10AT, which comprises four cell lines representative of discrete stages 
of disease progression, i.e. normal-like breast cells, pre-neoplastic cells, and low and high-grade 
breast cancer cells, initially established from clonal isolates originating from a squamous 
carcinoma derived from a xenograft of a RAS-transformed variant of a cell line model of normal 
human mammary epithelium, MCF10A.93, 95 Global proteomic analysis of this system was 
achieved via a quantitative ESI LC-MS/MS approach in which total peptides derived from each 
cell line model were labeled with iTRAQ-reporter tags, thus facilitating the coordinate 
determination of abundance for a given peptide identification across all conditions. 93 Results 
yielded a total of 1200 protein identifications and revealed protein abundance characteristics 
indicative of disease progression in breast cancer, such as the observed progressive increase in 
vimentin abundance with more aggressive cell types, a marker of mesenchymal cells and 
indicative of breast cells which have undergone EMT.93 Further, these studies resulted in the 
identification of differentially abundant protein profiles which had not been previously 
implicated in breast cancer, namely adenylate kinase-1 (AK1), copper transport protein 
(ATOX1) and histone H2B type 1-M (HIST1H2BM); which were validated in a larger cohort of 
26 matched normal and breast cancer tissue samples by IHC analysis.93  
 
Proteomic analysis of clinical breast cancer tissues have revealed that discrete tissue 
compartments, i.e. tumor epithelium and adjacent stromal tissues, bear unique proteomic 
signatures122, a finding which underscores the value of obtaining homogenous cellular regions 
utilizing laser microdissection (LM) prior to performing proteomic analysis to ensure cellular 
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populations of interest are enriched for.117, 122 A recent global, proteomic analysis utilizing a 
label-free (spectral count) LC-MS method of LM-captured tumor regions derived from fresh, 
frozen breast tissue specimens obtained from one normal patient and three with IDC resulted in 
the identification of a 60 member protein panel specific for IDC tissues.115 The authors further 
validated the differential abundance observed for one factor, nucleoside diphosphate kinase A 
(NDKA), in a subset of patient tissue samples by western and IHC analysis.115 Clinical samples 
analyzed by -omics technologies are often obtained by biopsy or surgical intervention and as 
these samples are often too precious or exhausted through subsequent clinicopathological 
analyses, it is often difficult to amass a large number of fresh clinical tissue specimens to 
perform analyses with sufficient power. One resource of clinical breast cancer specimens which 
addresses this issue are formalin-fixed, paraffin embedded (FFPE) tissues, a common tissue 
preservation technique utilized for the preparation of clinical samples for pathological analysis.80, 
123
 Wide-scale usage of FFPE tissue preservation has resulted in the assembly of vast archives of 
clinical breast cancer tissue that represent excellent resources for conducting retrospective 
proteomic analyses.80 Proteomic versus genomic analyses of FFPE tissues have further revealed 
that the impact of formalin fixation on tissues, which produces protein-protein (lysines, backbone 
amides), protein-DNA and DNA-DNA cross-links, more greatly influences the quality of RNA 
that can be obtained from these tissues than protein.124 123, 125-127  Global protein profiling of 
FFPE tissue samples utilizing various proteomic strategies, such as reverse-phase protein arrays 
and LC-MS methodologies, further when paired with LM, have proven robust.123, 126-131 One 
proteomic analysis of FFPE breast cancer tissues has been described132 and encompassed a proof 
of concept analysis towards optimizing protein/peptide recovery from FFPE tissues for utility in 
a MALDI-TOF Imaging MS strategy. Results revealed peptide spectra were optimally obtained 
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after subjecting samples to a heat-induced antigen retrieval and subsequent trypsin digestion 
regimen.132 Further, data presented in chapters 3 and 4 of this thesis describe two LC-MS-based, 
global proteomic analyses utilizing FFPE clinical breast cancer tissues towards the 
characterization of disease specific protein characteristics.  
 
The primary focus of proteomic research in breast cancer has been directed towards the 
discovery of single or multiple biomarker panels which can accurately diagnose disease and 
which can be profiled from sample sources obtained by minimally invasive means, such as via a 
blood sampling, utilizing commonly employed clinical techniques, such as 
immunohistochemical-based analyses.74, 133, 134 Therefore, many discovery efforts have focused 
on proteins which are actively secreted by tumor cells as protein candidates which may enter into 
lymphovascular circulation, such as “secretome” analyses of spent tissue culture media 
containing proteins secreted from cell line models of human breast cancer cells, as well as 
studies of clinical biofluid samples, such as serum, CSF, and fluids proximal to primary tumor 
sites, such as NAF and breast TIF. 84, 91, 96-121. Biomarker discovery efforts which have 
investigated serum derived from breast cancer patients for disease specific protein patterns have 
been confounded by the dynamic range bias imposed by abundant proteins present in serum and 
thus often employ a depletion strategy to remove these high abundant species prior to LC-MS 
analysis, resulting in enrichment of lower abundant proteins which may be of interest to disease 
biology.97, 99, 135, 136 In the case of a recent global proteomic analysis utilizing a MudPIT LC-
MS/MS strategy of serum samples derived from a cohort of patients with benign breast disease 
or presenting with IDC with or without lymph-node metastasis, serum samples were depleted of 
albumin utilizing an EtOH precipitation method.97 Results yielded a total of 2,078 proteins being 
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identified by at least two peptides across all samples analyzed and differentially abundant protein 
populations by hierarchical cluster analysis of spectral count peptides revealed 41 proteins (± 
~16) which significantly differentiated these various patient groups.97 Further analyses of one 
protein, tenascin-XB (TNXB), which was decreased in IDC patient serum with lymph node 
involvement, in a large patient cohort of 131 serum samples revealed this expression profile was 
specific for this subgroup of patients.97 As dynamic range biases imposed by high abundant 
proteins are factors to consider prior to proteomic analysis of both serum and CSF samples, 
alternative strategies towards characterizing protein populations which are more enriched and 
specific for breast tumor cells have been contrived. 84, 91, 104-114, 119-121 In vitro global, proteomic 
analyses of conditioned media derived from cultured breast cancer cell line models has proven a 
robust strategy for the characterization of proteins that are actively shed from breast cancer 
cells.84, 85, 134, 137, 138 One such study utilized an LC-MS/MS approach to characterize conditioned 
media derived from 3 human breast cell lines, i.e. MCF10A and two cancerous cell lines, BT474 
and MDA-MB-468 cells, which were grown to confluency and cultured in serum-free media, 
resulted in the identification of ~600 proteins across these media conditions.84 One issue with 
this strategy is the concern that proteins present in conditioned media may contain carryover 
serum proteins, as cells are typically established in serum containing media prior to being 
transitioned to serum-free conditions, as well as intracellular proteins released by cells which 
have undergone lysis.84, 134 Characterization of the known cellular localization status via 
bioinformatic analyses for these protein identifications did not indicate that specific enrichment 
of known secreted or ECM-localized proteins was achieved and rather showed that proteins were 
identified from various cellular compartments.84 To increase the confidence that those proteins 
identified from conditioned media were actually the product of shedding by tumor cells, authors 
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performed parallel analyses of corresponding total cell lysates; through comparisons of 
proteomic data sets obtained from lysed cells and conditioned media, it was possible to identify 
secreted protein candidates with higher confidence.84 Interestingly, comparative analysis of 
secreted protein candidates from these studies with previously published proteomic analyses of 
NAF and breast TIF derived from tumor samples (described below) revealed a high degree of 
concordance between conditioned media proteins and those observed in proximal fluid 
analyses.84 Further, these authors inspected the levels of one secreted protein candidate, the 
secreted epithelial proteinase inhibitor elafin, by ELISA analysis of serum samples from three 
groups of breast cancer patients reflective of increasing levels of the cancer antigen CA 15-3 as a 
cohort of patients exhibiting progressively more aggressive disease characteristics.84 CA 15-3 is 
a derivative of the cell-surface associated protein, MUC-1 which has been proposed as a serum 
biomarker of breast early breast cancer. 76, 84 Though initial observations revealed a decrease in 
elafin levels in conditioned media derived from tumorigenic versus normal breast cells, no 
significant pattern of elafin levels in serum from the patient cohort was observed.84  
 
Proteomic analyses of clinical fluids immediately proximal to a primary breast tumor, such as 
NAF, have also yielded provocative breast cancer biomarker candidates. 104-114, 119-121. NAF, or 
breast ductal fluid, is produced by the alveolar-ductal system of the breast and has been an 
attractive resource for breast cancer biomarker discovery as it is a breast-specific proximal fluid 
that is attainable by non-invasive means.139-141 Further, profiling of NAF for carcinoembryonic 
antigen (CEA) and HER2 in abnormal nipple discharge has been approved for the diagnosis of 
breast cancer in Japan.139, 142, 143 Several proteomic analyses of NAF have been reported since 
2001 which have focused on optimizing strategies for analysis of NAF,104-114 characterizing 
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inter-patient variability of NAF proteome characteristics144 and establishing proteomic profiles 
and identifying biomarkers in NAF which are specific for breast cancer.107-114 A recent LC-MS 
analysis of the human NAF proteome which compared samples derived from normal and breast 
cancer patients by spectral count revealed this proximal fluid to contain as many as 896 proteins 
with an average of 37% identified as being localized to the extracellular matrix and 27% to the 
plasma membrane of cells with 41% further overlapping with proteins which have previously 
been observed in normal blood serum.108 It was further shown that the NAF proteome of breast 
cancer patients exhibits significant heterogeneity relative to NAF samples derived from healthy 
individuals and reported the identification of several proteins which have been proposed as 
biomarkers for breast cancer, i.e. urokinase-type plasminogen activator (uPA),76, 145  cathepsin-
D,146 cancer antigen (CA) 15.3147 and tissue plasminogen activator (tPA).148  
 
An additional proximal fluid source for analysis of secreted biomarkers from breast tumor cells 
has been breast TIF (tissue interstitial fluid or tumor interstitial fluid).127-129 Breast TIF is 
obtained from fresh breast tissues acquired immediately post-surgical resection where regions of 
normal and tumor-containing tissues are diced and incubated in phosphate-buffered saline (PBS) 
at 37º C to facilitate the efflux of secreted proteins from cell populations.127-129, 149 The logic 
underlying this strategy is that proteins effluxed from tumor tissues will contain high 
concentrations of secreted, tumor-specific proteins that may become diluted in serum and may 
thus be analyzable by more targeted assays in blood.121, 149 One possible issue arising from this 
strategy are the potential biases imposed by incubation of live tissues in PBS due to this solution 
not being representative of the in situ tissue environment, proffering similar concerns as tissue 
culture-based secretome strategies utilize cells cultured in serum-free media. However, recent 
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assessment of various buffer conditions ranging from PBS and serum free tissue culture media 
(DMEM) to tissue preservation solutions utilized for organ transplantation, such as Celsior 
solution S and histidinetryptophan-ketoglutarate (HTK) solution, revealed no specific buffer 
condition significantly modulated the array of proteins identified by cellular localization in 
recursive proteomic analyses of TIF samples harvested from ovarian and kidney tissues 
incubated in these various buffers, indicating PBS as a suitable buffer to utilize for TIF 
acquisitions.149 The seminal proteomic analysis of breast TIF utilized a 2DE, MALDI-MS 
strategy which analyzed TIF obtained from 16 patients with IDC resulting in the identification of 
267 proteins which predominantly comprised proteins previously known to be localized to the 
cellular cytoplasm as well as present in serum.121 Later analyses by this group using identical 
proteomic workflows focused on comparisons of matched normal and breast tumor tissue-
derived TIF from 69 breast cancer patients.150 Initial analyses were performed utilizing a 
matched pair of normal and tumor TIF derived from a single patient which yielded 110 proteins 
candidates that were robustly increased in tumor versus normal TIF. These initial 110 candidates 
then functioned as a training set for the assessment of 2DE gels profiles of tumor TIF acquired 
from the remaining 68 patients with the goal of identifying a subset of proteins exhibiting similar 
expression trends in at least 90% or more of the patients analyzed.150 Results revealed a panel of 
26 proteins which were observed at increased abundances in all 69 tumor TIF patient samples, a 
subset of 9 was further validated in a larger cohort of 70 malignant breast carcinomas by tissue 
microarray analysis.150 The authors further propose future analyses which will test the feasibility 
of profiling expression of this subset of proteins as biomarkers of breast cancer by simple blood 
tests.150   
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Though evidence has been provided indicating that a variety of compelling breast cancer 
biomarker candidates have emerged from proteomic-based discovery efforts, thus far, a lack of 
sufficient vetting of these factors, particularly in large patient cohort studies, has limited the 
translation of these biomarkers to the clinic.76, 133 Further, when metrics which classically define 
a “good” clinical biomarker, such as those detailing that a marker be highly sensitive for 
identifying individuals with disease and produce a low false-positive rate, i.e. be highly specific 
for these individuals, biomarker candidate performance often falters due to significant inter-
patient variability as well as due to inconsistencies in marker profiling strategies utilized.76, 133, 
134, 151
  
 
In the context of –omics technologies actively utilized as clinical breast cancer tools, gene-based 
biomarker discovery efforts utilizing cDNA microarray analysis have yielded two gene 
expression profiling strategies, the Oncotype DX and the FDA-approved Mammaprint platforms, 
which are now commonly utilized by the clinical community, further having expanded the 
repertoire of prognostic strategies available to clinicians.26, 28, 46, 76, 125, 152-154 For example, the 
Oncotype DX assay comprises a 21-gene panel designed for assessment of disease prognosis in 
breast cancer patients with early-stage ER-positive (ER+) disease lacking nodal involvement 
(pN0) which has further been shown to accurately predict 10-year disease recurrence rates in this 
subgroup of patients.125, 154 Further, Oncotype DX assay results are provided as a composite 
recurrence score that has been shown to be effective in determining higher risk patients that may 
benefit from extended hormonal therapies.125, 154 These diagnostic platforms underscore the value 
of assessing disease-associated biomarker panels rather than single factors as these strategies 
increase the sensitivity and specificity of the diagnostic endpoint in question.155 
25 
 
1.4: Proteomics of Breast Cancer – Functional Proteomics 
 
The utility of data derived from global proteomic analyses not only functions as a resource for 
the discovery of disease-specific protein signatures which can be directly utilized in clinical and 
diagnostic applications, but further, when combined with bioinformatic analyses of functional 
protein databases, such as gene ontology (GO) identifiers, protein-protein interaction and 
biological pathway networks, the potential to provide significant information regarding 
functional biological characteristics associated with a disease subtype or biological event 
becomes possible. 156, 157 These analyses facilitate the ability to investigate novel questions 
regarding protein functionality and activity in breast cancer, yielding insights which can provide 
the basis for further hypothesis-driven research to elucidate the role of factors of interest. For 
example, in the instance of a single proteomic analysis, consideration of trends in functional 
protein subtypes through comparative assessment with protein databases comprising known 
protein functions or peptide sequences with archives of conserved protein domains known to 
mediate specific protein functions, such as protein kinase or DNA-binding domains, can provide 
insights into predominant systems level biological activities.157 In the context of considering 
protein functionality along with protein abundance, if proteins which exhibit common functional 
characteristics occupy similar regions within the dynamic range of the protein abundances 
observed, such as multiple proteins at high abundances associated with, for example, regulation 
of endosomal transport or with specific cellular signaling cascades, this would support the 
hypothesis that the known functional roles associated with these proteins may play key roles in 
the biological system analyzed. Further, as protein abundance does not directly correspond to 
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protein activity, consideration of protein groups which share similar functionalities not only by 
abundance characteristics, but further in relation to their post-translational modification status, 
such as phosphorylation-state, adds further dimensions to assessment of whether a protein group 
may significantly contribute to the underlying biology of a system.157 In addition, these types of 
observations are strengthened by analysis of a large number of samples, being that consideration 
of protein functionality across larger sample sets enables more focused discovery of central 
themes conserved across similar systems, further aiding to highlight characteristics which are 
unique to subtypes that diverge from central system features. This course of logic is particularly 
powerful towards the characterization of conserved and divergent functional protein 
characteristics in cancer biology, particularly in the case of breast cancer, due to the high degree 
of molecular heterogeneity associated with these diseases.  
 
Methods to perform these analyses are diverse and are focused on statistical measurements of 
confidence determining whether a given protein or protein group and corresponding functional 
roles are significantly overrepresented within a given data set versus the possibility that this 
observation is occurring due to random chance, i.e. the null hypothesis.157-161 The most 
commonly utilized strategy to assess functional characteristics within large gene or protein data 
sets utilize GO terms, which are hierarchical categories of specific biological functions that 
correspond to three main functional sub-groups, those associated with 1) biological process 2) 
molecular function and 3) cellular component, and a given gene or protein is assigned to a 
category based on published findings and correlative functional protein domains.157, 162 Various 
tools, such as NIH DAVID163 and the CytoScape plug-in ClueGO161, facilitate calculation of 
enriched GO terms via referencing user-defined data sets against GO databases and provide 
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measures of significance as to whether a given GO category is overrepresented in a data set 
through occupancy of experimental candidates in that GO category.157 Further, proprietary 
functional analysis tools, such as Ingenuity Pathway Analysis (IPA Systems, 
www.ingenuity.com), afford the comparison of multiple functional databases to a user data set to 
discern significantly enriched biological functions, further enabling direct assessment of the 
primary findings in which a given association between a gene/protein and function was initially 
derived, enabling users tools to determine whether an observation is made in a similar species, 
disease subtype or biological system.157 Aside from assessment of enriched functional 
characteristics within proteomic data sets, several tools, including CytoScape and IPA, are also 
focused towards the identification of protein interaction networks derived from comparisons with 
established protein interaction databases compiled from large-scale yeast two-hybrid and 
synthetic lethal screens as well as maps of immunoprecipitated protein complexes and protein-
DNA interaction networks to enable characterization of signal transduction and protein 
interaction networks.158, 159, 164 
 
In the context of breast cancer, several global proteomic analyses of human breast cancer cell 
lines have been published which have focused on elucidation of functional protein characteristics 
associated with breast cancer pathogenesis.69, 89, 90 One such study detailing an LC-MS based 
proteomic analysis of four breast cell lines, one representative of normal mammary epithelium 
(HMEC) and three breast tumor cells (MCF7, MDA-MB-231 and BT-474) resulted in the 
identification of 2235 proteins across all cell lines, 234 of which were mutually observed in all 
conditions. 90 Mutually observed proteins were then 1) compared to microarray data previously 
published for these cell lines, 2) analyzed for the prevalence of underlying protein interaction 
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networks within this group and 3) investigated further for potential PTMs.90 Results revealed 
nine proteins which exhibited similar protein and gene expression trends across the cell line 
conditions which further clustered in discrete protein interaction networks via assessment of 
these factors against the Biomolecular Interactions Database.90 These results further revealed the 
modulation of several integrin isoforms (proteins associated with intercellular interactions) as 
being decreased across tumor cell lines as well as factors which have been shown to be key 
mediators of tumorigenicity in breast cancer cells, such as epidermal growth factor receptor 
(EGFR).90 Assessment of PTMs within this subset of proteins via variable modification searches 
considering phosphorylation, acetylation, O-GlcNAc, palmitoylation, C-mannosylation, 
hydroxylation, glucosylation, and S-nitrosylation PTM events revealed cancer cell line specific 
modifications, such as phosphorylation of alpha catenin (CTNNA1), a key member of cellular 
adherens junctions, as well as O-GlcNAc modification of coronin-1B, a cytoskeletal protein 
associated with cell motility and cytokinesis.90 Additionally, an inferred protein-network analysis 
comparing microarray data generated from two large cohort studies of primary breast cancer 
patients with and without metastatic disease with previously established protein-protein 
interaction databases resulted in the identification of metastasis-specific protein sub-networks.156 
Specifically, the authors identified factors previously associated with breast cancer pathogenesis, 
such as p53 and HER2, as well as interacting network proteins which exhibited discrete 
expression trends in metastatic versus non-metastatic groups.156 Data was further provided 
showing that metastasis-specific sub-networks identified from one microarray analyses could 
accurately predict individuals with metastatic disease in the corresponding data set ~50% of the 
time.156 An additional analysis derived from microarray studies characterizing key oncogenic 
signaling factors in breast cancer further revealed provocative evidence that assessment of 
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pathway activation state can provide another dimension to standard disease subtype classification 
conventions that extend beyond ER, PR and HER2 profiling alone. 165  These findings were 
further proposed as a strategy to identify higher risk patients in these subgroups towards the 
development of more tailored therapeutic strategies.165 Though the utility of functional proteomic 
as well as genomic data are just beginning to be realized, the correlation of a given gene or 
protein group factors of interest with previously published observations associating a factor with 
a specific functional biological role may aid in selecting targets for future investigations for their 
role in a disease state, further expanding the knowledge-base surrounding both the factor of 
interest and the associated disease process.         
 
1.5: Introduction to Data Chapters 
 
The following thesis comprises studies focused on the application of proteomics and subsequent 
bioinformatics towards discerning differential protein abundance and associated functional 
characteristics which underlie tumorigenesis and neoplastic progression in breast cancer. The 
data detailed in chapters one166, 167 and two are focused on in vitro analyses of conserved protein 
abundance and functional characteristics across divergent molecular subtypes of breast cancer as 
well as towards the identification of proteins regulated by the breast cancer associated 
microRNA, miR-145. Data chapters three168 and four are focused on the proteomic analysis of 
formalin-fixed paraffin embedded clinical breast cancer tissues towards the characterization of 
protein abundance characteristics which are indicative of disease stage, stage-specific 
characteristics, such as lymph-node involvement, as well as of disease recurrence in breast 
cancer.   
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2.0. CHAPTER 1: DEFINING CENTRAL THEMES IN BREAST CANCER BIOLOGY 
BY DIFFERENTIAL PROTEOMICS: CONSERVED REGULATION OF CELL 
SPREADING AND FOCAL ADHESION KINASE 
The molecular heterogeneity encountered in breast cancer underscores the importance of better 
defining the gene and protein abundance patterns that are conserved across breast cancer cells 
with the goal of defining context-specific characteristics that will aid in the development of more 
targeted therapeutic strategies. The combination of global proteomic analyses with bioinformatic 
analyses of functional protein databases can provide insights into the overarching biological 
characteristics present in a sample analyzed. The definition of protein abundance and subsequent 
functional biological characteristics that are conserved across breast cancer cells will clarify the 
central themes underlying neoplastic progression and further aid to discern disease subtype-
specific characteristics. 
 
Although several groups have reported global, proteomic analyses of various breast cancer cell 
line models82-88, few focused analyses of the functional biological characteristics associated with 
differentially abundant proteins across breast cancer cell types have been described.69, 89, 90 We 
have therefore undertaken a comparative global, mass spectrometry (MS)-based proteomic 
analysis of three divergent cell line models of breast cancer reflective of the most common 
clinical breast cancer subtypes encountered25, 27, 28, 30 and a model of normal mammary epithelial 
cells with the goal of better defining protein abundance and functional biological characteristics 
which are mutually shared across breast cancer cells. The three breast cancer cell lines 
investigated include: MCF7, an estrogen receptor (ER) positive breast cancer cell line that 
exhibits luminal-like characteristics and is non-invasive, yet tumorigenic in the presence of 
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exogenous estrogen169-173; SK-BR-3, a luminal-like, HER2/neu positive breast cancer cell line 
that is non-invasive, yet tumorigenic; and MDA-MB-231, a basal/mesenchymal-like ER-/PR-
/HER2- (“triple negative”), highly invasive and aggressively tumorigenic breast cancer cell 
line.169-172, 174 The proteomic analyses of these three breast cancer cell lines were compared with 
a model of normal mammary epithelial cells: MCF10A, a non-tumorigenic, spontaneously 
immortalized breast cell line reflective of normal mammary epithelium that exhibits basal-like 
characteristics.169, 171, 172, 175 
 
A systems analysis utilizing Ingenuity Pathway Analysis (IPA) revealed significant modulation 
of extracellular matrix (ECM), plasma membrane and nuclear-localized proteins across tumor 
cell lines relative to MCF10A cells. These characteristics have been previously found to be 
indicative of breast cancer cells, with ECM modulation specifically as being shown to be an 
integral event underlying breast cancer pathogenesis.11, 12, 176 Functional analyses of differentially 
abundant proteins across breast cancer cell lines revealed modulation of proteins associated with 
regulation of cell morphology, specifically with losses of proteins previously shown to promote 
“cell spreading”. These observations are supported by the anchorage-independent phenotypes 
maintained by the breast cancer cell lines analyzed.170, 174 The present investigation further 
resulted in the identification of 82 proteins which are mutually, differentially abundant across 
three divergent cell line models of breast cancer. This subset included proteins which have 
previously been shown to regulate the focal adhesion complex protein focal adhesion kinase 
(FAK), a fundamental regulator of cell spreading and a key player in breast cancer 
pathogenesis.177 Differentially abundant protein populations reveal that modulation of ECM and 
nuclear protein composition, as well as proteins associated with regulation of cell spreading and 
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focal adhesion kinase expression levels and activity are characteristics which are mutually 
conserved across breast cancer cells.  
 
Materials and Methods 
 
Cell Lines and Lysate Preparation 
MCF10A, MCF7, SK-BR-3 and MDA-MB-231 cell lines were purchased from ATCC 
(American Type Culture Collection) and cultured in DMEM/F12K media supplemented with 
10% fetal bovine serum (Hyclone, Logan, UT). Lysates were prepared from ~70% confluent 
plates by scraping cells into 150 µl of 1X SDS buffer (10% SDS and 10 mM Tris-HCl, pH 7.4). 
Samples were sonicated twice for 10 s at an energy of 1.5 W utilizing a micro-tip sonicator 
(Misonix, Indianapolis, IN) followed by centrifugation at 14,000 x g for 10 min. Protein 
concentration of the supernatants was determined by the bicinchoninic assay (BCA) (Pierce, 
Rockford, IL). 
 
Sample Preparation for LC-MS/MS 
Thirty-five µg of total cell lysate were resolved in two consecutive gel lanes via 1D SDS-PAGE 
on a 4-12% Bis-Tris gel (NuPAGE, Invitrogen, Carlsbad, CA). Gels were stained with 
Coomassie blue (SimplyBlue SafeStain, Invitrogen) and duplicate lanes were cut into ten 
equivalently sized slices. Gel slices were de-stained in 50% acetonitrile (ACN) and 50 mM 
ammonium bicarbonate (AMB) at ambient temperature for 3 h followed by dehydration in 100% 
ACN. Reactive cysteine residues were reduced via re-hydration of gel spots in 10 mM DTT, 25 
mM AMB followed by incubation at 56 °C for 30 min and alkyated via incubation in 55 mM 
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iodoacetamide, 25 mM AMB for 30 min at ambient temperature in darkness. Gel slices were 
then washed with 25 mM AMB, dehydrated in 100% ACN and re-hydrated in 25 mM AMB 
containing 20 µg/mL porcine sequencing grade modified trypsin (Promega, Madison, WI) on ice 
for 30 min. Digestions were incubated for 16 h at 37°C. Tryptic peptides were extracted with 
70% ACN, 5% formic acid (FA), dried by vacuum centrifugation and re-suspended in 40 µl of 
0.1% trifluoroacetic acid (TFA). In addition, 10 fmol/µL of three internal standard peptides, 
VTIASLP13C10R, FLVGPDGIPIMox13C10R and TGISPALI13C6K, were added to each sample 
digest to monitor LC-MS/MS analytical performance parameters.  
 
Liquid chromatography-tandem mass spectrometry analyses  
Peptide digests were resolved by nanoflow reverse-phase liquid chromatography (Ultimate 3000, 
Dionex Inc., Sunnyvale, CA) coupled online via electrospray ionization to a hybrid linear ion 
trap-Orbitrap mass spectrometer (LTQ-Orbitrap, ThermoFisher Scientific, Inc., San Jose, CA). 
Duplicate injections of 5 µL of peptide extracts were resolved on 100 µm i.d. by 360 µm o.d. by 
200 mm long fused silica capillary columns (Polymicro Technologies, Phoenix, AZ) slurry-
packed in-house with 5 µm, 300 Å pore size C-18 silica-bonded stationary phase (Jupiter, 
Phenomenex, Torrance, CA). After sample injection, peptides were eluted from the column using 
a linear gradient of 2% mobile phase B (0.1% FA in ACN) to 40% mobile phase B over 125 min 
at a constant flow rate of 200 nL/min followed by a column wash consisting of 95% B for an 
additional 30 min at a constant flow rate of 400 nL/min. The LTQ-Orbitrap MS was conFigured 
to collect high resolution (R=60,000 at m/z 400) broadband mass spectra (m/z 375-1800) from 
which the seven-most abundant peptide molecular ions dynamically determined from the MS 
scan were selected for tandem MS using a relative CID energy of 30%. Dynamic exclusion was 
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utilized to minimize redundant selection of peptides for CID. Analytical metrics of LC-MS/MS 
performance (mass measurement accuracy and retention time) were monitored for each sample 
analyzed using three stable isotope, internal standard peptides by calculating reconstructed mass 
chromatogram areas for each standard peptide using QuanBrowser (XCalibur v2.1, 
ThermoScientific). QuanBrowser processing method parameters tolerated ± 15 ppm mass 
accuracy and ± 5.0 min in retention time relative to monoisotopic masses and retention times 
estimated from manual inspection of internal standard peptides from representative raw data. 
 
Peptide Identification and Spectral Count Analysis 
Peptide identifications were obtained by searching the LC-MS/MS data utilizing SEQUEST 
(BioWorks, v3.2, ThermoScientific) on a 72-node Beowulf cluster against a UniProt-derived 
human proteome database (version 10/08, 56,301 protein entries) obtained from the European 
Bioinformatics Institute (EBI) using the following parameters: trypsin (KR); full enzymatic-
cleavage; two missed cleavages sites; 20 ppm peptide mass tolerance peptide tolerance, 0.5 amu 
fragment ion tolerance; and variable modifications for methionine oxidation (m/z 15.99492) and 
cysteine carboxyamidomethylation (m/z 57.02146); data analysis revealed 10.7% (±1.3%) of all 
cysteine-containing peptides were non-reacted. Resulting peptide identifications were filtered 
according to specific SEQUEST scoring criteria: delta correlation (∆Cn) ≥ 0.08 and charge state 
dependent cross correlation (Xcorr) ≥ 1.9 for [M+H]1+, ≥ 2.2 for [M+2H]2+, and ≥ 3.5 for 
[M+3H]3+. These criteria resulted in a false discovery rate of 0.4% for all peptides identified as 
determined by searching the data set against a decoy human database where the protein 
sequences were reversed.178 Differences in protein abundance between the samples were derived 
by spectral counting (SC) and peptides whose sequence mapped to multiple protein isoforms 
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were grouped as per the principle of parsimony.179 Equivalency in peptide load was also 
determined by comparison of the spectral count values for the protein actin, cytoplasmic 1 
(ACTB) across all samples.180 Differential protein abundance was calculated by normalizing 
total peptide spectral counts observed in the LC-MS/MS analysis of MCF7, SK-BR-3 and MDA-
MB-231 conditions against total spectral counts from MCF10A. A value of 0.5 was added to 
each spectral count value prior to log2 transformation to enable ratio values to be calculated for 
proteins identified in one cell line, but not another.181 Proteins which exhibited a > 95% 
confidence interval from the mean for each comparison performed were considered statistically 
significant. 
 
Bioinformatic Analyses 
Uniprot accessions corresponding to proteins identified by at least two peptides were mapped to 
HUGO (HGNC) gene symbols utilizing Ingenuity Pathway Analysis (IPA) (Ingenuity® 
Systems, www.ingenuity.com). Accessions which failed to map were converted to IPI identifiers 
with the mapping utility available at www.uniprot.org and re-mapped to IPA to maximize 
protein identifications available for downstream bioinformatic analyses. Protein localization and 
subtype assignments were derived from IPA-mapped data sets. Statistical analyses for the 
enrichment of specific protein sub-types amongst differentially-expressed proteins were 
performed utilizing a two proportions–z test, with a significance level set to p ≤ 0.05. Functional 
analysis of significant protein lists were performed utilizing the “Core Analysis” function in IPA 
using default parameters. Significant (p < 0.05) biofunctions containing a minimum of two 
associated proteins were correlated from each “Core Analysis” by functional annotation across 
global significant protein lists. Network and protein interaction analyses were also performed 
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utilizing IPA for mutually, differentially abundant proteins in which a maximum of 35 proteins 
for network assignment were allowed. 
 
Western Blot Analyses 
Twenty-five micrograms of total cell lysate derived from biological replicates of cell line 
conditions analyzed was resolved via 1D SDS-PAGE and resulting gels were transferred to a 
PVDF membrane at a constant 30V / 160 mA for 2 h. Blots were blocked for 1 h at 37 °C in 1X 
blotto (5% dehydrated milk, 0.1% Tween-20 and 1X TBS) followed by incubation in primary 
antibody diluted in 1X blotto overnight at 4 °C. Blots were washed in 1X TBST (1X TBS, 0.1% 
Tween-20 (Sigma Aldrich, St. Louis, MO) followed by incubation in secondary antibody for 1 h 
at ambient temperature. Blots were washed again in 1X TBST followed by incubation in 
chemiluminescent substrate (SuperSignal West Pico or Dura, Rockford, IL) for 5 min at ambient 
temperature. Primary and secondary antibody conditions utilized were as follows: goat anti-
rabbit IgG-HRP (1:10,000) (Abcam, Cambridge, MA: ab6721), goat anti-mouse IgG-HRP 
(1:50,000) (Pierce: 31432), goat, anti-Rat IgG HRP (1:10,000) (RND Systems, Minneapolis, 
MN: HAF005), anti-beta actin (1:10,000) (Abcam: ab6276), anti-Cytokeratin 19 (1:1000) 
(Abcam: ab15463), anti-CD10 (MME/Neprilysin) (1:1000) (Abcam: ab951), anti-integrin alpha 
11 (1:250) (RND Systems: MAB4235), anti-TGFBI (1:1000) (Abcam: ab89062), anti-FAK 
(1:1000) (Abcam: ab40794), anti-Hic5 (1:1000) (TGFBI1I) (BD Biosciences, Franklin Lakes, 
NJ: BDB611164), anti-TNC (1:200) (RND Systems: MAB2138). 
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Results and Discussion 
 
Global proteomic analysis of human breast cell line models  
Global proteomic analyses of three breast cancer cell line models (MCF7, SK-BR-3 and MDA-
MB-231) reflective of the most common clinical breast cancer subtypes encountered were 
compared with a model of normal mammary epithelial cells MCF10A to identify central themes 
in protein abundance and functional characteristics underlying the transformed phenotypes of 
these key model systems of breast cancer (Fig. 5 - Workflow). Duplicate, LC-MS/MS analyses 
of tryptic peptides corresponding to 70 µg of total protein from each cell line condition on an 
LTQ-Orbitrap resulted in a total of 39,158 peptide identifications and 5,030 proteins identified 
Figure 5: Analytical workflow utilized for differential and comparative proteomic analysis
four breast cell lines analyzed.
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by at least two peptides (Fig. 6). Equivalency of protein digest input for each cell line was 
determined by comparison of the total number of peptides identified across all four cell lines 
analyzed by LC-MS/MS, revealing a relative standard deviation (RSD) of 12.3%, with total 
mean RSD peptide identification rates between replicate sample injections of 2.7% (± 2.7%). 
Equivalent peptide digest input was further confirmed by comparison of total peptides identified 
for beta-actin (ACTB, Fig. 11) commonly utilized as a loading control for western blot 
analysis,180 which revealed an RSD value of 23.1% across all cell lines analyzed. Metrics of 
analytical performance were further monitored by comparison of retention time and mass 
chromatogram area variance for three internal standard peptides that were added to each sample 
Figure 6: Protein identification characteristics across four breast cell lines 
analyzed. A four-way Venn diagram detailing the total number of proteins identified and 
co-identified in each breast cell line analyzed. Proteins reported were derived from two 
technical LC-MS/MS replicates of each cell line and were identified by at least two 
peptides.  
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prior to LC-MS/MS analysis. These results show an aggregate peak area RSD of 25.1% (± 9.6%) 
for the three control peptides across the 80 LC-MS/MS analyses that were conducted. Taken 
together, these results provide strong evidence that the global protein digest input into the LC-
MS/MS analyses was equivalent across all cell lines analyzed. This observation critically 
underpins determination of significant, differentially abundant proteins by spectral counting 
without the need for normalization. These analyses resulted in the coincident identification of 
1,778 proteins across all cell lines (Fig. 6, region IX). Proteins identified in both MCF7 and SK-
BR-3 (2,540 proteins, Fig. 6, region VI) revealed the greatest overlap in a qualitative two-way 
comparison and between MCF7, SK-BR-3 and MDA-MB-231 (2,078) in a three-way 
comparison (Fig. 6, region X). Interestingly, the greater overlap of proteins identified between 
MCF7 and SK-BR-3 cells is consistent with these cell lines both exhibiting characteristics of 
luminal-type breast cancer cells.169, 171, 172  
 
Uniprot accessions numbers corresponding to proteins identified were mapped to HUGO gene 
symbols (HGNC) utilizing IPA, yielding a final list of 4,859 proteins that were included in 
subsequent bioinformatic analyses. Comparison of known cellular localization and protein 
subtype characteristics for final mapped data sets revealed that proteins were consistently 
identified from similar cellular compartments and functional sub-types between the four cell 
lines analyzed. 
 
Comparative analysis of proteins differentially abundant in individual comparisons of 
breast cancer cell lines versus non-transformed MCF10A cells. 
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Spectral count ratios of proteins identified in the breast cancer cell lines MCF7, SK-BR-3 and 
MDA-MB-231 exhibiting a >95% confidence interval relative to proteins identified in MCF10A 
cells were considered as significantly differentially abundant, with the average cut-off for 
increased abundance being log2 (3.48 ± 0.48) and decreased abundance log2 (-3.04 ± 0.14). The 
results revealed a total of 784 unique protein groups as differentially abundant across all breast 
cancer cell lines analyzed, with 379 of these (mean of 163 ± 5) as increased and 405 (mean of 
219 ± 26) as decreased in abundance (Fig. 7A). Significant, differentially abundant proteins 
amongst the breast cancer cell lines include hallmark candidates that are well established in the 
Figure 7: Identification characteristics for significantly, differentially 
abundant proteins in breast cancer cell lines. A. A three-way Venn diagram 
comparing the number of significantly, differentially abundant proteins 
observed across breast cancer cell lines relative to MCF10A cells. The central 
“grayed” region designates the 82 proteins which were observed as being 
mutually, differentially abundant across all breast cancer cell lines relative to 
MCF10A cells. B. Comparison of proteins identified by cellular localization 
across global proteins identified versus significantly, differentially abundant 
proteins observed in breast cancer cell lines. Significant, differential enrichment 
is designated by *, p<0.05.  
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literature, such as increased abundance of E-cadherin (CDH1) observed in MCF7 cells (log2 4.6 
fold-change), high levels of HER2/neu (ERBB2) in SK-BR-3 cells (log2 5.4) and high EGFR 
levels in MDA-MB-231 cells (log2 4.2).169, 172, 182 Significant increases in the number of ECM 
localized proteins and decreases in nuclear-localized proteins were observed amongst 
differentially abundant proteins across breast cancer cell lines (Fig. 7B). This profile is supported 
by the notion that modulation of nuclear and ECM protein composition are characteristic of 
breast cancer cells and occurs during breast tumorigenesis.10-12, 16, 176 To define overarching 
functional characteristics amongst differentially abundant proteins significant (p<0.05) biological 
functions (biofunctions) observed via “Core Analysis” (IPA) of protein lists from each tumor cell 
line were correlated. A total of 10 significant biofunctions overlapped between proteins with 
increased abundance and 147 between proteins decreased in abundance across all tumor cell line 
conditions. These results indicate that proteins decreased in abundance across the breast cancer 
cell lines share greater functional similarities in comparison with proteins increased in abundance 
relative to MCF10A. The top ten scoring overlapping biofunctions between differentially 
abundant proteins from all breast cancer cell lines (Fig. 8) were associated with two predominant 
functional categories, cancer (4/10 total) and “cell morphology” (3/10), and included specific 
sub-categories, such as tumorigenesis, as well as those relating to cell spreading, respectively. In 
comparing these results with the top ten scoring biofunctions observed for proteins exhibiting 
increased or decreased abundance, coordinate losses and gains in proteins associated with the 
functional category of cancer are observed across all breast cancer cell lines (Fig. 8). Proteins 
associated with the biofunction category “cell morphology” were predominantly decreased in 
abundance across tumor cell lines, however, with the majority being associated with the specific 
sub-category of cell spreading (Fig. 8). 
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Cell spreading describes the transition a cell undergoes from a rounded to a more “flattened” 
morphology during anchoring to a substratum.183, 184 This event is mediated via reorganization of 
the cellular actin cytoskeleton and through the establishment of focal adhesion complexes, 
Figure 8: Identification of functional characteristics across proteins 
significantly, differentially abundant in breast cancer cell lines. Top 
10 significant biofunctions observed across differentially abundant 
protein lists identified from each breast cancer cell line. Figure reports 
average p-values observed and mean number of proteins which clustered 
with a given biofunction.  
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predominantly comprising cellular integrins, that mediate communication between the 
intracellular and extracellular environments through interactions with ECM proteins.12, 183, 184 
ECM anchoring is required for normal epithelial cell survival, which is an event termed 
anchorage-dependence, with survival in the absence of these interactions, or anchorage-
independence, being a hallmark characteristic of cellular transformation17, 184 In the normal 
mammary epithelium, ECM interactions are maintained with the collagen- and laminin-rich 
basement membrane (BM) separating the epithelial compartment from adjacent stromal tissues 
and these interactions provide cues that function to inhibit apoptosis and promote cell survival.16, 
185, 186
 Anchorage-dependent MCF10A cells have been shown to actively secrete laminins in 
culture, specifically laminin-5, the expression of which has been further shown to be 
characteristic of non-tumorigenic mammary epithelial cells.12, 185-187 Assessment of laminin-5 
abundance in our data revealed high abundances in MCF10A cells and significantly decreased 
levels in MDA-MB-231 cells, as well as low levels in MCF7 and SK-BR-3 conditions. Further, 
MCF10A cells exhibit morphological characteristics of normal mammary epithelial cells in 
culture, having a flattened appearance and forming defined epithelial sheets.182, 188, 189 MCF7 and 
SK-BR-3 cells deviate from these characteristics in that they form tight colonies of polygonal 
cells in culture, with SK-BR-3 cells exhibiting even greater morphological heterogeneity that 
includes semi-adherent, spheroidal cell populations, and are thus considered less differentiated 
than MCF7 cells.182. Lastly, MDA-MB-231 cells exhibit a mesenchymal or fibroblastic-like 
morphology in culture as they have undergone epithelial to mesenchymal transition, forming 
erratic networks of spindle shaped cells.182 Comparison of cell spreading and subsequent cell 
survival in normal versus H-RAS-transformed fibroblasts has revealed a direct correlation 
between the degree of cell spreading and survival in normal cells that is not observed in 
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transformed cell types.189 These findings clarify the observed loss of proteins associated with cell 
spreading in the breast cancer cell lines analyzed as, unlike MCF10A cells, all three breast 
cancer cell lines analyzed are capable of sustaining anchorage-independent growth.170, 174 
Therefore, as MCF7, SK-BR-3 and MDA-MB-231 cell lines represent a range of more to less 
differentiated breast cancer cell types,182 respectively, and as a significant loss of proteins 
associated with the regulation of cell spreading is observed across all conditions, these alterations 
may represent early events in the transformation of mammary epithelial cells.  
 
Comparative analysis of mutually, differentially abundant proteins observed across breast 
cancer cell lines versus non-transformed MCF10A cells. 
 
A comparative analysis of mutually, differentially abundant proteins revealed a total of 82 
proteins that were identified in all three breast cancer cell lines relative to MCF10A cells (Table 
2). The majority of these proteins were decreased in abundance (n=68) in all breast cancer cell 
lines versus a small subset which were increased (n=13). A single exception to this was filamin 
C gamma (FLNC), a protein commonly increased in mesenchymal cell types,169 which was 
significantly increased in MDA-MB-231 cells (log2 4.1) though decreased in MCF7 and SK-BR-
3 cells (log2 -4.2 (± 1.1). Unlike the other breast cancer cell lines analyzed, this observation is 
consistent with MDA-MB-231 cells having undergone epithelial to mesenchymal transition and 
may be a novel characteristic of this event. Consistent with previous reports comparing normal 
and breast cancer cells and tissues, we observed increased levels of keratin-19 (KRT19) (Fig. 11) 
169, 190
, glutathione s-transferase mu 3 (GSTM3)85, as well as decreases in levels of tropomyosin 
1.83 Analysis of protein localization amongst this mutually dysregulated protein subset revealed 
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significant increases in both plasma membrane and ECM proteins and decreases in nuclear 
proteins relative to total, differentially abundant protein populations identified across all breast 
cancer cell lines (Figure 9A). This observation further underscores the modulation of ECM and 
nuclear protein composition as central themes of breast cell transformation, further adding 
modulation of plasma membrane protein composition as a characteristic conserved across breast 
cancer cells.10, 12, 16 Evaluation of this subset of 82 differentially abundant proteins revealed 
decreases in several canonical basement membrane proteins, such as the proteoglycan heparin 
sulfate proteoglycan 2 (HSPG2) as well as several collagen isoforms, including two type 4 
collagens, alpha 1 (COL4A1) and alpha 2 (COL4A2) (Table 2). HSPG2 and type 4 collagens are 
well known constituents of the basement membrane in normal mammary epithelium and loss of 
expression is commonly observed during breast cancer pathogenesis.191-193 Interestingly, a 26-
kDa region of COL4A1, termed arresten, has been shown to possess tumor suppressor and anti-
angiogenic properties in murine models of tumor metastasis.194-196 Further, a 24-kDa region of 
COL4A2, termed canstantin, has also been similarly shown to inhibit tumor growth and 
discourage angiogenesis in xenograft models of tumorigenesis and in in vitro analyses of 
endothelial cells, respectively.194, 196, 197 Indeed, coordinate losses of various basement membrane 
proteins, several of which have been shown to possess tumor suppressor functions, across breast 
cancer cell lines analyzed underscores their anchorage-independent phenotypes and is consistent 
with their tumorigenic phenotypes. 
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Table 2: Mutually, Differentially Abundant Proteins Observed Across B.Cancer Cells
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Modulation of proteins associated with regulation of cell spreading is conserved across 
breast cancer cell lines.  
Further analysis of this protein subset revealed that the top ten significant biofunctions amongst 
this group clustered into two predominant functional categories, cell development (4/10) and cell 
morphology (4/10), including specific biofunctions associated with cell adhesion (adhesion of 
fibroblast cell lines) and overlap between these functional categories and various subcategories 
associated with the regulation of cell spreading (Fig. 9B). The significance of cell spreading 
amongst this mutually dysregulated protein subset underscores this cellular event as being a 
central characteristic of breast cancer cells. The subcategories associated with cell spreading 
encompass proteins derived from in vitro characterization of this event in eukaryotic and 
fibroblast cell types.198-213 A total of eleven proteins were associated with all four cell spreading 
sub-categories combined (Fig. 9B) and each were significantly decreased in abundance across all 
tumor cell lines relative to MCF10A cells, with the exception of FLNC which was observed at 
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increased levels in MDA cells. Of these 11 proteins, nine have been shown to directly promote 
cell spreading (Table 1, HGNC symbols designated as (a), 198, 199, 201-205, 207, 209-211, 213 with the 
remaining two having been found to either decrease or variably impact cell spreading (Table 1, 
HGNC symbols designated as (b).200, 204, 206-208, 212   
  
 
Several of these proteins that promote cell spreading have been shown to be mutated or lost with 
disease progression in breast cancer and include fibrillin (FBN1), fibroblast growth factor 2   
(FGF2), transforming growth factor, beta-induced (TGFBI) and tropomyosin 1 alpha (TPM1).83, 
214-216
 In breast cancer, single nucleotide polymorphisms have been observed in the gene 
encoding the structural microfibrillar, ECM glycoprotein FBN1.216  Expression of the ECM 
Figure 9A: Protein identification characteristics for proteins that were 
mutually, differentially abundant across breast cancer cell lines. A: Comparison 
of proteins identified by cellular localization across global significantly, 
differentially abundant proteins versus mutually (co-differentially) abundant proteins 
observed in breast cancer cell lines. Significant, differential enrichment is designated 
by *, p<0.05.  
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protein TGFBI, also known as BigH3 (Fig. 11), the cytoskeletal protein TPM1 as well as the 
growth factor FGF2 have all been shown to be lost with neoplastic progression in breast cancer 
and in cancerous versus normal breast cell types.83, 214, 215 Conversely, three proteins previously 
shown to promote cell spreading, the type 1 transmembrane protein anthrax toxin receptor 1  
(ANTXR1), integrin alpha 11 (ITGA11, Fig. 11) and the putative cell adhesion protein periostin, 
osteblast-specific factor (POSTN), have been found to be increased in breast cancer.217-219 
Expression of ANTXR1, also known as Tem8, has been shown to be increased in breast cancer 
tissues, and further to be a marker of microvasculature in the tumor endothelium of breast 
cancers.217 Further, POSTN has been shown to be increased in expression at both the gene and 
protein levels in breast cancer tissues.218, 219 
 
The remaining two proteins observed in this subset of 11 cell spreading associated 
proteins have been shown to either inhibit or variably impact cell spreading, one being the 
transcriptional regulator transforming growth factor beta 1 induced transcript 1 (TGFB1I1, Fig. 
11) and the other the ECM protein tenascin–C (TNC, Fig. 11), respectively. TGFB1I1, or Hic-5, 
has been shown to decrease cell spreading in fibroblast cells and, in the context of breast cancer, 
TGFB1I1 has been shown to play an integral role in mediating glucocorticoid signaling in breast 
cancer cells and capable of promoting epithelial to mesenchymal transition when ectopically 
expressed in MCF10A cells. 206, 220, 221 Additionally, TNC has been shown to variably impact cell 
spreading in neural and leukemia cancer cells 200, 204, 212 and, in the context of breast cancer, to 
exhibit increased levels in breast tumor stroma as well as in breast cancer cells, including MDA-
MB-231 cells, further being shown to promote angiogenesis and metastasis in breast cancer 
through the activation of oncogenic signaling cascades such as mitogen-activated protein kinase 
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(MAPK) and Wnt.222, 223 TNC binds various ECM proteins such as HSPG2 as well as 
fibronectin, which we observe as being significantly abundant in MCF10A cells relative to the 
tumor cell lines analyzed. When taken together, the array of ECM proteins expressed in 
MCF10A cells relative to all breast cancer cell lines analyzed, combined with the propensity of 
Figure 9B: Protein identification characteristics for proteins that were 
mutually, differentially abundant across breast cancer cell lines. Top 10 
significant biofunctions observed across mutually, differentially abundant 
proteins across breast cancer cell lines. Figure reports average, significant p-
values observed and mean number of proteins observed which clustered with a 
given biofunction.  
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TNC to directly interact with these ECM factors, may produce an ECM context discouraging 
induction of aberrant signaling by TNC. The predominant loss of proteins that function to 
promote cell spreading across tumor cell lines is supported by the aberrant morphologies and 
anchorage-independent phenotypes maintained by these cell types.182, 224 Further, as the majority 
of these factors have been shown to be lost with disease progression in breast as well as other 
forms of cancer,83, 214-216, 225, 226this subset of proteins may play an integral role in the onset of 
key events that support mammary epithelial cell transformation, such as promoting a loss of 
contact inhibition as well as anchorage-independent growth.   
Figure 10: Network analysis of mutually, differentially abundant 
proteins observed across breast cancer cell lines. Top protein network 
derived from “Core Analysis” of significant co-identified proteins. Orange 
arrows denote those proteins which clustered specifically with FAK.  
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Network analysis reveals several mutually, differentially abundant proteins cluster with 
focal adhesion kinase, (FAK) a key regulator of cell spreading.  
Investigation of cell signaling networks associated with this subset of differentially expressed 
proteins revealed the top scoring network to include 28 out of the 82 (34%) differentially 
expressed proteins observed across all breast cancer cell lines (Fig. 10). This 28- member 
network comprises predominantly ECM, plasma membrane and cytoplasmic proteins and 
includes several basement membrane proteins, such as HSPG2 and several collagen isoforms, in 
addition to seven proteins associated with regulation of cell spreading, e.g. FBN1, FGF2, 
ITGA11, PALLD, TGFBI, TNC and TPM1. Proteins involved in this network as inferred by IPA 
include the nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kB), platelet-
derived growth factor, BB dimer variant (PDGF-BB) and focal adhesion kinase (FAK). When 
considering this network in the context of the recurring functional theme of cell spreading 
observed amongst differentially abundant proteins across the breast cancer cell lines analyzed, 
the assignment of FAK specifically to this network is noteworthy as this protein plays a central 
role in regulating the event of cell spreading in epithelial, endothelial and fibroblast cell types.177, 
227
 In the context of breast cancer, FAK has been shown to play key roles in disease 
pathogenesis, further being found to function as an obligate co-factor underlying the malignant 
transformation of neoplastic breast cells.177, 228, 229 FAK is a non-receptor tyrosine kinase that 
localizes to focal adhesion complexes and is typically activated in response to integrin-ECM 
protein interactions, thus functioning to translate extracellular, growth factor and integrin-
mediated signaling events to the intracellular environment, typically via PI3K and RAS-MAPK 
signaling cascades.177, 230 Activation of FAK has further been shown to occur via epidermal and 
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platelet-derived growth factor signaling directly (EGF and PDGF) and FAK is often found to be 
constitutively activated in transformed, anchorage-independent cell types, including breast 
cancer cells, which are commonly driven by aberrant growth factor signaling.10, 177, 231, 232 In 
evaluating FAK levels in the present analyses, there are modest increases of FAK in MCF7 (log2 
1.32) and MDA-MB-231 (log2 2.17) cells, but decreased levels in SK-BR-3 cells (log2 -1.0) 
relative to MCF10A (Fig. 8). FAK has previously been shown to be expressed in SK-BR-3 cells 
and indeed to be more highly expressed in MDA-MB-231 versus MCF7 cell types.233, 234 
Figure 11: Verification of a subset of mutually, differentially abundant 
proteins observed across all breast cancer cell lines. Western blot 
validation derived from biological replicates of cell lines conditions. 
Adjacent “spectral count” values derived from raw spectral counts observed 
for each protein of interest during initial LC-MS/MS analyses.  
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Interestingly, in non-transformed cells, the activation state of FAK has been shown to be directly 
related to cell spreading as studies of FAK activation in cultured primary endothelial and 
fibroblast cells have revealed that less “spread” cells exhibit  decreased levels of activated FAK 
relative to cells which are more “spread” in culture.227 As FAK has been shown to often be 
overexpressed and constitutively active in transformed cells,177, 231 it is reasonable to hypothesize 
that typical regulation of FAK activation during cell spreading via integrin-ECM interactions 
shifts towards alternate activation mechanisms as transformed cells display greater anchorage-
independent characteristics. This hypothesis is supported by the losses observed in the present 
investigation in proteins across tumor cell lines that have previously been shown to promote cell 
spreading in other cell types. Furthermore, the transformed phenotypes maintained by the breast 
cancer cell lines analyzed have been shown by the literature to be driven largely in part by 
abnormal growth factor signaling, such as through aberrant estrogen responses in MCF7 cells 
and constitutively active EGF signaling in SK-BR-3 cells due to HER2 amplification and MDA-
MB-231 cells due to overexpression of EGFR or through mutant KRAS, which may thus 
produce a signaling context that promotes activation of FAK in the absence of anchorage-
dependent mechanisms.169, 171-174, 232 In support of this notion, silencing of FAK expression in 
breast cancer cell lines, including MDA-MB-231 cells, exhibiting aberrant RAS signaling results 
in growth arrest of these cell types and in HER2 positive breast cancer cell types, including SK-
BR-3 cells, results in diminished growth capacity, underscoring the integral role FAK plays in 
maintaining the transformed phenotype of breast cancer cells.232 
 
Assessment of differentially abundant proteins observed across the breast cell lines analyzed that 
clustered specifically with FAK (Fig. 10) included several factors that have been shown to 
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impact expression levels or activation of FAK, namely the membrane metallo-endopeptidase 
(MME, also known as neprilysin), TNC, KRT19, the ECM proteoglycan versican (VCAN), and 
canstantin, the 24-kDa region of COL4A2.190, 204, 235-237 Proteins exhibiting decreased abundances 
across these breast cancer cell lines that have been shown to inhibit FAK activation include 
MME, TNC (Fig. 8) as well as canstantin.204, 235, 236 Ectopic expression of MME in prostate 
cancer cells has been shown to decrease activation of FAK, with basal MME expression being 
further shown to be inversely correlated with FAK levels in several prostate cancer cell line 
models.236 In breast cancer, MME expression has been shown to be decreased in breast tumor 
tissues with this loss correlating with a decrease in overall disease-free survival.238 However, 
MME expression has also been shown to be increased in breast tumor stroma and this 
observation has further been shown to correlate with an increase in disease recurrence.239 TNC 
has been shown to decrease activation of FAK in glioblastoma cells grown on a matrix 
consisting of fibronectin and TNC versus fibronectin alone.63 Further, co-treatment of human 
umbilical vein endothelial cells with canstantin (the 24-kDa region of COL4A2) and serum 
resulted in decreased activation of FAK which was induced by serum alone.235 
 
Conversely, KRT19 and VCAN have been shown to either decrease expression or increase 
activation of FAK, respectively, and exhibited abundance profiles across breast cancer cell lines 
that are contrary to supporting constitutive activation of FAK in these cell lines.190, 237 
Restoration of KRT19 in the KRT19-negative breast cancer cell line BT-549 has been shown to 
decrease expression of FAK and to promote cell dormancy, which is consistent with the high 
levels of KRT19 observed in dormant, circulating tumor cells.190 This group further showed that 
FAK expression is increased in MDA-MB-231 cells by silencing of KRT19 expression.190 
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Interestingly, KRT19 has recently been shown to be actively released by MCF7, SK-BR-3 and 
MDA-MB-231 cells and evaluation of KRT19 expression in metastastatic tumor cells from the 
bone marrow of breast cancers patients has revealed high levels of KRT19 to correlate with 
disease occurrence, progression and an overall decrease in survival.240 This apparent inverse 
relationship between KRT19 and FAK expression levels in breast cancer cells may be explained 
by context-specific roles for these factors, being that KRT19-mediated cell dormancy may be 
required to survive distal metastasis, whereas the role of FAK in maintaining the tumorigenic 
potential of breast cancer cells may require a cellular or tissue context. 
 
Analysis of integrin beta-1-dependent cell adhesion in U87 glioblastoma cells revealed ectopic 
expression of a c-terminal domain variant of VCAN results in increased cell adhesion and 
activation of FAK.237 Wu and colleagues further showed that MDA-MB-231 cells grown in spent 
media produced by U87 cells overexpressing this variant of VCAN results in increased cell 
adhesion as well, but the subsequent impact on FAK activation in these cells was not noted.237 
Versican has been shown to be highly expressed in the stroma of breast cancer patients with this 
further correlating with a decrease in overall disease-free survival.241 It is reasonable to 
hypothesize that high levels of VCAN in breast tumor stroma may drive FAK activation in in 
situ disease. However, this VCAN variant effect was found to be dependent upon interaction 
with integrin beta-1, which in the present investigation was observed as decreased in abundance 
across all breast cancer cell lines versus MCF10A cells. These findings indicate a subset of 
proteins that have been previously shown to regulate FAK expression and activity in other cell 
types and disease pathologies that therefore warrant further investigation for their roles in 
regulating FAK activation in breast cancer pathogenesis.  
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Conclusion 
 
A comparative, global proteomic analysis and subsequent functional systems analysis utilizing 
IPA software of proteins differentially abundant across three human breast cancer cell line 
models (MCF7, SK-BR-3 and MDA-MB-231) reflective of the most common clinical disease 
subtypes encountered relative to a cell line model of normal, human mammary epithelial cells 
(MCF10A) revealed modulation of ECM, plasma membrane and nuclear protein composition is 
conserved across breast cancer cells. Systems biology analysis revealed predominant losses in 
proteins associated with the regulation of cell spreading and modulation of proteins that have 
previously been shown to impact FAK expression levels and activity in various cell types and 
disease pathologies, such as MME, TNC, COL4A2, KRT19 and VCAN. These analyses thus 
provide a subset of candidates that warrant further investigation for their roles in regulating cell 
spreading and FAK expression and activity in breast cancer. In conclusion, these data provide 
insights into protein abundance and subsequent functional characteristics that are conserved 
across three divergent models of breast cancer cells relative to a model of normal mammary 
epithelial cells, revealing characteristics that represent molecular events central to the 
pathogenesis of breast cancer. 
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3.0 CHAPTER 2: QUANTITATIVE PROTEOMIC ANALYSIS OF MICRORNA-145 IN 
BREAST CANCER. 
Recent efforts in the field of RNA-mediated interference has revealed an endogenous gene 
expression regulatory mechanism that is mediated by small, non-coding RNA segments termed 
microRNAs (miRNA).242 MicroRNAs disrupt gene expression post-transcriptionally by binding 
to discrete, yet potentially multiple target messenger RNA (mRNA) transcripts resulting in their 
degradation or translational repression (Figure 12). miRNA biogenesis begins with transcription 
of a primary miRNA transcript (pri-miRNA) by RNA polymerase II that is then cleaved by the 
nuclear RNase III complex Drosha-DGCR8 or by processing of miRNA-bearing, intronic 
sequences (Mirtrons) by mRNA splicing machinery to produce ~75 nucleotide (nt) stem-loop 
structures termed precursor miRNAs (pre-miRNAs). Pre-miRNAs are then exported to the 
cellular cytoplasm via exportin-5 where they are further cleaved by the RNase III-type Dicer and 
TAR RNA binding protein (TRBP) enzyme complex into mature miRNAs; ~22 nt double-
stranded RNA (dsRNA) containing ~2 nt, 3 prime (3’) - end overhangs. These mature miRNAs 
are then incorporated into a miRNA-induced silencing complex (miRISC) which consists of 
various ribonucleoproteins, such as Dicer and the Argonaute (AGO) protein family which 
mediate the catalytic functions of the miRISC.242-245 This complex is then typically directed to 
target sites within the 3’ untranslated regions (UTR) of mRNAs resulting in the degradation or 
translational repression of gene targets.242-245 The extent to which either mRNA degradation or 
translational repression occurs is dependent on the degree of mismatch between a miRNA and its 
corresponding mRNA target sequence; as greater mismatch results in translational repression and 
lesser mismatch, and therefore greater complimentarity, in degradation.243, 246  
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Recent evidence supports the role of 
miRNAs in oncogenesis, such as in 
cases where miRNAs target tumor 
suppressor genes or conversely when 
the expression of miRNAs responsible 
for targeting proto-oncogenes are 
lost.247 In the context of breast cancer, 
comparison of miRNA profiles 
between normal and tumorigenic breast 
cancer cell lines and tissues has 
revealed aberrant expression of various 
miRNAs accompany breast 
tumorigenesis, including microRNA-
145 (miR-145) which is commonly lost 
in transformed breast cancer cells.248-
250
 Further, decreased miR-145 
expression has been correlated with the onset of a pre-neoplastic state in breast myoepithelial cell 
populations indicating that this loss may represent an early event in breast cancer pathogenesis 
and thus may play a central role in underlying disease processes.248 Early in vitro investigations 
of miR-145 in breast cancer revealed expression of this miRNA to be induced by p53 via direct 
interaction with a putative promoter region upstream of the miR-145 gene sequence and that 
restoration of miR-145 in MCF7 breast cancer cells resulted in a growth inhibitory phenotype 
which was shown to be induced by direct targeting of the proto-oncogene c-myc251 or the Rho-
Figure 12: microRNA Biogenesis. Adapted from Filipowich, 
W et al 2008.
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interacting scaffolding protein Rhotekin (RTKN).252 Further, restoration of miR-145 expression 
in divergent cell line models of normal and cancerous breast cells revealed this growth inhibitory 
phenotype was dependent on either the presence of wild-type p53 or estrogen receptor (ER) 
expression, eliciting a pro-apoptotic effect in these cell types and further being shown to directly 
target ERα.253 Later analyses of miR-145 restoration in breast cancer cell lines, including MDA-
MB-231 and SK-BR-3 cells, revealed this miRNA induces decreases in cell motility and invasive 
capacity as well as decreased tumor burden in a xenograft models of tumor metastasis.254, 255 
Decreased cell invasion and metastatic capability was shown to be due to miR-145 directly 
targeting the metastasis-associated gene mucin-1, junctional adhesion molecule A (JAM-A) and 
the actin filament cross-linking protein, fascin.254, 255 
 
Currently, 1048 miRNAs have been identified in humans (Sanger miRBase, 10/2010), though 
very little is known regarding the complete array of mRNA targets that may be regulated by a 
specific miRNA. While this regulatory event is highly effective, it is rather imprecise due to an 
imperfect targeting mechanism that is based on the free energy of binding between the first eight 
nucleotides in the 5’ region of a miRNA, which contains the so-called “seed” region, and the 3’ 
UTR of its target mRNA; an interaction which can be confounded by possible G:U wobble base-
pairing (see Figure 10: miRNA target discovery workflow Figure).256 Current methodologies 
applied in the prediction of miRNA targets utilize computational algorithms (such as 
TargetScan257, MIRANDA258 or PITA259) that score the receptiveness of an mRNA transcript as 
a target for a specific miRNA based on this 5’- end complimentarity and the thermodynamic 
stability of the interaction between the remaining 3’ region of the miRNA and the 3’UTR target 
sequence.256, 260 An evaluation of putative miR-145 targets utilizing TargetScan, MIRANDA 
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(microcosm) and PITA indicates that 1923 (± 2039) unique mRNA transcripts are targeted by 
this miRNA (10/2010), representing an impressive ensemble of targets that have not been 
experimentally observed. As miRNAs regulate their targets post-transcriptionally, the use of RT-
PCR or mRNA microarray profiling to validate miRNA targets provides only limited insight into 
the global effects of this regulatory event as mRNAs translationally repressed by a miRNA 
would fail to be detected by these techniques.256 Therefore, a miRNA target elucidation strategy 
which incorporates global, quantitative proteomic analysis provides a strategy in which to 
measure the impact of a miRNA on mRNA translation. The combination of quantitative 
proteomic and genomic analyses towards miRNA target discovery has confirmed this hypothesis, 
revealing that discrete populations of mRNAs are degraded and/or translationally repressed in 
miRNA loss or gain-of-function studies.77, 78, 261 In the context of breast cancer, the utilization of 
an iTRAQ-based quantitative proteomic strategy to discover miRNA targets has been reported 
for miR-21, a pro-oncogenic miRNA, in which miR-21 expression was silenced in MCF-7 cells 
and proteins increased in abundance were investigated as potential targets of miR-21 via 
screening of corresponding 3’UTR sequences for miR-21 “seed” regions.79  
 
We therefore undertook a miRNA target discovery approach utilizing an LC-MS, quantitative 
proteomics to elucidate targets of miR-145 in MDA-MB-231 and SK-BR-3 human breast cancer 
cells. Investigation of miR-145-specific effects was achieved via sequence analysis of 3’UTR’s 
derived from genes corresponding to proteins which were decreased in abundance in MDA-MB-
231 cells expressing miR-145 (MDA-145) and revealed 33 target candidates that contained a 
miR-145 “seed” motif. Differential proteomic analysis of SKB-145 cells revealed 280 target 
candidates that contained a miR-145 “seed” motif. Correlation of these of miR-145 target 
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candidate populations revealed 11 mutually overlapping targets between MDA-145 and SKB-
145 cells. Furthermore, preliminary analyses of the phenotypic impact of miR-145 restoration on 
cell survival, cell cycle progression and cell migration in MDA-MB-231 cells are presented. 
Results revealed miR-145 did not modulate basal cell survival or cell cycle characteristics in 
MDA-MB-231 cells, ectopic expression however did produce disorganized cell monolayers in 
confluent cultures as well as modest impairment of cell migratory characteristics relative to 
MDA-NEG cells. These observed phenotypic effects in MDA-145 cells have been corroborated 
by other groups253-255, which, upon further examination, indicates that the degree of impact on 
miR-145 on cell migration in MDA-MB-231 cells is concentration dependent.254   
 
Materials and Methods 
 
Generation of MDA-MB-231 and SKBR3 breast cancer cell lines stably expressing miR-
145.  
Pri-miR-145 sequences [native hairpin-loop sequence (pre-miRNA, ~88nt) flanked by ± 80bp of 
genomic DNA]262, 263 were commercially synthesized with 5’ BamHI and 3’ XhoI sites 
(Integrated DNA Technologies, Coralville, IA) and cloned into the pcDNA6.2-GW/EmGFP-miR 
expression vector (Invitrogen, Carlsbad, CA) via BamHI and XhoI restriction sites. MDA-MB-
231 and SK-BR-3 cells (ATCC) cultured in DMEM/F-12 K media supplemented with L-
glutamine and 10% fetal bovine serum were transfected with 5ug of the miR-145 containing 
vector or a negative control variant of pcDNA6.2-GW/EmGFP-miR encoding a scrambled pre-
miRNA sequence. Forty-eight hours post-transfection, cells were selected for stable expression 
in medium containing Blasticidin (MDA-MB-231: 10 µg/mL and SK-BR-3: 5ug/ml, Invitrogen) 
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for up to four weeks, being monitored for EmGFP expression by fluorescence microscopy 
throughout. Further, silencing of restored miR-145 expression in SK-BR-3 cells was achieved 
via transient transfection of 100nM of a miR-145-specific anatgomiR (Ambion) followed by 
incubation for 72 hours. miR-145 expression was confirmed by quantitative PCR via purification 
of small RNA from stable expressing cell populations utilizing the mirVana miRNA Isolation 
Kit (Ambion, Austin TX) and a TaqMan microRNA quantitative PCR assay (ABI, Carlsbad, 
CA) specific for mature miR-145 and RNU43 (a small nucleolar RNA (C/D box 43) which 
functioned as a small RNA loading control) on an ABI 7900HT real-time PCR machine as per 
manufacturer’s recommendations.  
 
Sample preparation and liquid chromatography-tandem mass spectrometry (LC-MS/MS) 
analyses  
Cell lysates were prepared from ~70% confluent plates by scraping cells into 150 µl of 1X SDS 
buffer, sonicating utilizing a micro-tip sonicator followed by centrifugation at 14,000 x g for 10 
min. Protein concentration of the supernatants was determined by the bicinchoninic assay 
(BCA). Thirty-five µg of total cell lysate derived from each conditions was resolved via 1D 
SDS-PAGE on a 4-12% Bis-Tris gel. Gels were stained with Coomassie blue and gel lanes were 
cut into ten equivalently sized slices. Gel slices were de-stained in 50% acetonitrile (ACN) and 
50 mM ammonium bicarbonate (AMB) at ambient temperature for 3 h followed by dehydration 
in 100% ACN. Reactive cysteine residues were reduced via re-hydration of gel spots in 10 mM 
DTT, 25 mM AMB followed by incubation at 56 °C for 30 min and alkyated via incubation in 55 
mM iodoacetamide, 25 mM AMB for 30 min at ambient temperature in darkness. Gel slices 
were then washed with 25 mM AMB, dehydrated in 100% ACN and re-hydrated in 25 mM 
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AMB containing 20 µg/mL porcine sequencing grade modified trypsin on ice for 30 min. 
Digestions were incubated for 16 h at 37°C. Tryptic peptides were extracted with 70% ACN, 5% 
formic acid (FA), dried by vacuum centrifugation and re-suspended in 0.1% trifluoroacetic acid 
(TFA). Peptide digests were resolved by nanoflow reverse-phase liquid chromatography 
(Ultimate 3000, Dionex Inc., Sunnyvale, CA) coupled online via electrospray ionization to an 
LTQ-Orbitrap mass spectrometer for MDA-NEG and MDA-145 samples or to an LTQ-XL for 
SKB-NEG vs. SKB-145 and SKB-145 vs. SKB-145KD sample analyses. Duplicate injections of 
peptide extracts were resolved on 100 µm i.d. by 360 µm o.d. by 200 mm long fused silica 
capillary columns slurry-packed in-house with 5 µm, 300 Å pore size C-18 silica-bonded 
stationary phase. After sample injection, peptides were eluted from the column using a linear 
gradient of 2% mobile phase B (0.1% FA in ACN) to 40% mobile phase B over 125 min at a 
constant flow rate of 200 nL/min followed by a column wash consisting of 95% B for an 
additional 30 min at a constant flow rate of 400 nL/min. The LTQ MS was configured to collect 
broadband mass spectra [m/z 375-1800; LTQ-Orbitrap at high resolution (R=60,000)] from 
which the seven-most abundant peptide molecular ions dynamically determined from the MS 
scan were selected for tandem MS using a relative CID energy of 30%. Dynamic exclusion was 
utilized to minimize redundant selection of peptides for CID. 
 
Peptide Identification and Spectral Count Analysis 
Peptide identifications were obtained by searching the LC-MS/MS data utilizing SEQUEST 
(BioWorks, v3.2, ThermoScientific) on a 72-node Beowulf cluster against a UniProt-derived 
human proteome database (version 10/08, 56,301 protein entries) obtained from the European 
Bioinformatics Institute (EBI) using the following parameters: trypsin (KR); full enzymatic-
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cleavage; two missed cleavages sites; 20 ppm peptide mass tolerance peptide tolerance, 0.5 amu 
fragment ion tolerance; and variable modifications for methionine oxidation (m/z 15.99492) and 
cysteine carboxyamidomethylation (m/z 57.02146); data analysis revealed 10.7% (±1.3%) of all 
cysteine-containing peptides were non-reacted. Resulting peptide identifications were filtered 
according to specific SEQUEST scoring criteria: delta correlation (∆Cn) ≥ 0.08 and charge state 
dependent cross correlation (Xcorr) ≥ 1.9 for [M+H]1+, ≥ 2.2 for [M+2H]2+, and ≥ 3.5 for 
[M+3H]3+. Differential protein abundance was calculated by normalizing total peptide spectral 
counts observed in miR-145 expressing versus negative control conditions (or in SKB-145KD 
vs. SKB-145 in this case). A value of 0.5 was added to each spectral count value prior to log2 
transformation to enable ratio values to be calculated for proteins identified in one cell line, but 
not another.181 Proteins which were decreased below log2  -0.25-fold change in MDA-145 vs. 
MDA-NEG and SKB-145 vs. SKB-NEG conditions (or increased log2 +0.25 fold in SKB-145KD 
vs. SKB-145), as per previous analyses which observed miRNA-specific effects on protein 
abundance as occurring at this fold change 77, were utilized for downstream analysis. 
 
Identification of miR-145 target candidates:  
Uniprot accessions corresponding to proteins decreased in abundance in MDA-145 conditions 
(or increased in SKB-145KD) were converted to Ensemble gene (ENSG) ID’s via biomart.org 
(Database: ENSEMBL GENES 59 (SANGER UK) Homo Sapiens (GRCh37) and subsequent 
3’UTR sequences corresponding to converted ENSG ID’s were similarly obtained. This 
workflow was arrived at empirically and yielded the greatest number of Uniprot accessions 
which mapped to corresponding 3’UTR sequences. Data sets were correlated utilizing 
Cytoscape164 and 3’UTR gene sequences were mined for intact, 6-mer and 7-mer miR-145 target 
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“seed” motifs, i.e. 1) cuggac 2) acugga 3) aacugg 4) acuggac 5) aacugga 6) aaacugg utilizing a 
search algorithm constructed in-house. Proteins containing at least one 6-mer miR-145 “seed” 
motif were considered a putative miR-145 target candidate. miR-145 target candidates were 
correlated from independent analyses of MDA-145 and SKB-145 conditions to discern mutually 
conserved miR-145 targets. Targets of interest were manually interrogated for their potential role 
in breast cancer via assessment of published literature as well as utilizing Ingenuity Pathway 
Analysis software. 
 
MTT growth assay of stable, miR-145-expressing MDA-MB-231 cells: 
MDA-145 or MDA-NEG cells were plated in triplicate at 5 x 103 cells per well in a 96-well plate 
on day 1. On days 2 thru 5, 10 µl of MTT reagent (5 mg/ml 3-[4,5-dimethylthiazol-2-yl]-2,5-
diphenyl tetrazolium bromide, Sigma, St. Louis. MO) was added to each well, plates were 
incubated for an additional 3 h at 37 °C followed by addition of 100 µl of MTT solvent (0.1 N 
HCl in 2-propanol) and measurement of solubilized formazan crystals was performed at 570 nm 
(background at 690 nm) utilizing a microplate spectrophotometer (SpectraMAX, Molecular 
Devices, Sunnyvale, CA).   
 
Cell cycle analysis of stable, miR-145-expressing MDA-MB-231 cells: 
MDA-NEG or MDA-145 cells were plated at 1x105 cells per well in a 6-well plate on day 1. On 
days 2 thru 5, cells were trypsinized, washed with 1X PBS, fixed with ice-cold 70% EtOH for 10 
min followed by re-suspension in 1X PBS, 0.1 mg/ml propidium iodide and 0.04 mg/ml RNAse 
A.264 Stained cells were immediately analyzed on a BD LSR II flow cytometer (Franklin Lakes, 
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NJ) in which 10,000 FSC versus PE (562–588 nm emission) events were acquired. Data was 
analyzed using WinMDI 2.8 flow cytometry analysis software.  
 
Wound healing assay of stable, miR-145-expressing MDA-MB-231 cells: 
MDA-NEG or MDA-145 cells were plated at 2.5 x 105 per well in a 6-well plate on day 1. On 
day 2, confluent monolayers were “wounded” utilizing a sterile 20 µl micropipette tip and 
wounds were demarcated to facilitate monitoring of identical areas by microscopic imaging. 
Wound areas were imaged immediately upon wounding and at ~12-24 h intervals (data shown 
are 16 and 48 hour timepoints).         
Results and Discussion: 
 
Identification of miR-145 targets in breast cancer cell lines ectopically expressing miR-145 
by differential proteomic analysis.   
The focus of these analyses was towards the identification of regulatory gene targets of the breast 
cancer-associated microRNA, miR-145, in MDA-MB-231 and SK-BR-3 human breast cancer 
cells. The workflow utilized to achieve this goal (Fig 13) entailed restoration of miR-145 
expression in MDA-MB-231 (MDA-145) and SK-BR-3 (SKB-145) cells followed by differential 
proteomic analyses of miR-145 expressing and scrambled, negative control miRNA conditions. 
3’UTR gene sequences corresponding to proteins decreased in abundance were obtained from 
ENSEMBL and mined for miR-145 specific target “seed” motifs. Target candidates which 
overlapped between MDA-145 and SKB-145 analyses were investigated for their roles in breast 
cancer pathogenesis via assessment of published literature as well as Ingenuity Pathway Analysis 
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Figure 13: miRNA Target Discovery workflow. 
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software. Further, analysis of the impact of miR-145 restoration in MDA-MB-231 on cell 
survival, cell cycle regulation and migratory characteristics is also discussed.    
 
Differential proteomic analysis of MDA-MB-231 and SK-BR-3 stably expressing miR-145.  
Confirmation of miR-145 restoration in breast cancer cell lines via qPCR analysis revealed 
MDA-145 cells exhibited a 28.5-fold increase in miR-145 levels relative to MDA-NEG cells and 
in SKB-145 cells, a 111.0-fold increase relative to SKB-NEG cells after selection for stable 
expression (Fig 11). Further, qPCR analysis of SKB-145 following transfection with 100nM of a 
Figure 14: Quantitative PCR analysis of miR-145 expression in MDA-MB-231 and SK-BR-
3 cells stably-expressing a vector encoding pri-miR-145 or a scrambled, negative control
miRNA. Further, SKB cells stably expressing miR-145 were transfected with 100nM of a
miR-145 antagomiR (72h). The small RNA RNU43 functioned as a loading control which
miR-145 conditions were normalized against.
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miR-145 specific antagomiR and incubation for 72 h resulted in a 15% decrease in miR-145 
expression levels (Figure 14). The results of global proteomic analyses of the following cell line 
comparisons, MDA-145 vs. MDA-NEG, SKB-145 vs. SKB-NEG and SKB-145 vs. SKB-145KD 
are summarized in (Table 3). Assessment of total proteins identified by at least two peptides in 
MDA-145 and SKB-145 proteomic analyses revealed a RSD of 14.4%, whereas total proteins 
decreased below log2 -0.25-fold between these two analyses yielded an RSD of 47.2%. This 
disparity in proteins decreased in abundance between MDA-145 and SKB-145 is commensurate 
with the markedly increased expression levels of miR-145 achieved in SKB-145, i.e. 3.9-fold 
Table 3: Summary of proteomic analyses and miR-145 specific effects. Quantitative 
proteomic analysis of MDA-MB-231 and SK-BR-3 cells stably expressing miR-145 and 
the prevalence of proteins bearing a miR-145 “seed” motif in corresponding 3’UTR 
sequences.  
Condition Total Proteins by 2 
unique peptides
Total Proteins
-0.25 log2-fold
% Proteins Decreased
MDA-145 vs. MDA-NEG 1294 313 24%
SKB-145 vs. SKB-NEG 1588 627 39%
SKB-145 vs. SKB-145KD 952 387 (increased) 41% (increased)
Condition
Decreased (Increased 
for SKB-145KD)
Proteins with mapped 
3’UTR sequences
Decreased (Increased 
in SKB-145KD) Proteins 
with at least ONE 
3’UTR, miR-145 “seed” 
% Decreased Proteins 
with miR-145 “seed”
MDA-145 vs. MDA-NEG 272 33 12%
SKB-145 vs. SKB-NEG 571 280 49%
SKB-145 vs. SKB-145KD 304 47 15%
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higher levels in SKB-145 vs. MDA-145 cells. Assessment of miR-145 specific activity by 
identification of miR-145 “seed” motifs in 3’ UTR sequences corresponding to proteins 
exhibiting abundances below log2 -0.25-fold change revealed 12% of proteins decreased in 
MDA-145 versus 49% of proteins decreased in SKB-145 analyses contained a miR-145 “seed”. 
This ~4-fold increase in miR-145 “seed” containing proteins in SKB-145 analyses can be further 
explained by the high levels of miR-145 expression achieved in SKB-145 cells, further 
suggesting that the impact of miR-145 on gene regulatory functions may be concentration 
dependent. As the populations of target candidates discerned from MDA-145 and SKB-145 
analyses greatly differed in size, data sets were correlated to discern mutually observed targets, 
revealing 11 proteins which contained a 3’ UTR miR-145 “seed” motif as being decreased in 
Table 4: Mutually-observed miR-145 target candidates. 11 miR-145 target 
candidates mutually observed between MDA-145 and SKB-145 analyses. Proteins in 
bold exhibited reverse expression trends in SKB-145 cells in response to transient 
expression with a miR-145-specific antagomiR.   
HGNC ID Protein Name
Fold-Change 
(STDEV)
Cellular 
Localization
Functional 
Type Predicted?
6mer
SEED
7mer
SEED
CCT7 T-complex protein 1 subunit eta -0.57 ( 0.18) Cytoplasm other yes 1 
ILK Integrin-linked protein kinase -2.81 ( 0.87) Plasma Membrane kinase no 1 
MRPL54 39S ribomal protein L54, mitochondrial -2.32 ( 0.18) unknown other no 1 
NDUFS2 
NADH dehydrogenase [ubiquinone] iron-sulfur 
protein 2, mitochondrial -0.89 ( 0.3) Cytoplasm enzyme yes 1 
PCYT2 Ethanolamine-phosphate cytidylyltransferase -2.32 ( 0.52) Cytoplasm enzyme no 1 
PPP6C Serine/threonine-protein phosphatase 6 -0.29 ( 0.09) Nucleus phosphatase no 1 
RAB5C Ras-related protein Rab-5C -0.34 ( 0.02) Cytoplasm enzyme yes 1 
SLC16A3 Monocarboxylate transporter 4 -2.81 ( 1.69) Plasma Membrane transporter yes 1 
SLC33A1 Acetyl-coenzyme A transporter 1 -2.32 ( 0.52) Cytoplasm transporter no 1 
TXNDC12 Thioredoxin domain-containing protein 12 -0.93 ( 0.05) Cytoplasm enzyme yes 1 
VPS26A Vacuolar protein sorting-associated protein 26A -1.08 ( 0.35) Cytoplasm transporter yes 1 
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both cell lines analyzed (Table 3). Assessment of the status of these 11 candidates as being 
previously predicted as putative miR-145 targets was ascertained by correlation with predicted 
miR-145 targets derived from TargetScan, MIRANDA and PITA prediction algorithms, 
revealing that 6 of these proteins are predicted miR-145 targets, with the remaining 5 therefore 
representing potentially novel target candidates (Table 4). Assessment of the functional roles of 
these 11 target candidates revealed modulation of proteins associated with metabolic and 
mitochondrial functions, such as 39S ribomal protein L54, mitochondrial (MRPL54), NADH 
dehydrogenase [ubiquinone] iron-sulfur protein 2, mitochondrial (NDUFS2) and ethanolamine-
phosphate cytidylyltransferase (PCYT2) as well as proteins associated with regulation of 
molecular transport, such as monocarboxylate transporter 4 (SLC16A3), acetyl-coenzyme A 
transporter 1 (SLC33A1) and vacuolar protein sorting-associated protein 26A (VPS26A) (IPA 
software). Further analysis revealed several of these factors have been implicated in several 
cancers, such as chaperonin containing TCP1, subunit 7 (eta) (CCT7), which has been observed 
as being increased in non-small cell lung cancer tissues derived from smoking vs. non-smoking 
patients via cDNA analysis265, as well as the RAS related protein Rab-5C (RAB5C), which has 
been observed in lipid rafts of cervical cancer cells266, glycolipoprotein-rich regions of the 
cellular plasma membrane which promote the assembly of signaling molecules, and has been 
further implicated in the regulation of the pro-oncogenic mitogen–activated protein kinase 
signaling cascade in these cell types.267 Additional investigations of these 11 miR-145 target 
candidates revealed two factors which have previously been implicated in breast cancer 
pathogenesis, i.e. monocarboxylate transporter 4 (SLC16A3) as well as integrin-linked kinase 
(ILK).268-270 SLC16A3 mRNA has been previously observed in breast cancer tissues, being at 
increased levels in HER2-negative breast cancers specifically, and functional studies have 
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revealed this transporter mediates the cellular efflux of monocarboxylic acids, such as lactate; a 
by-product of pyruvate metabolism during glycolysis which is the predominant mechanism by 
which ATP is produced by metastatic tumor cells. 20-22, 269, 271 Analysis of SLC16A3 in MDA-
MB-231 cells, a model of metastatic breast cancer, revealed expression levels of SLC16A3 were 
significantly increased in this cell line relative to normal mammary tissues and further, that 
silencing of SLC16A3 in MDA-MB-231 resulted in a decrease in cell migration.269 These 
findings are interesting when considered in the context of recent evidence indicating the 
decreases in invasive and migratory activity observed in MDA-MB-231 cells ectopically 
expressing miR-145.254, 255 Though other groups have shown that alternate miR-145 targets 
underlie modulation of cell migration in MDA-MB-231254, 255, miR-145-mediated targeting of 
100
110
120
130
140
150
160
170
180
190
200
210
220
230
240
250
2 3 4 5
Days
R
el
at
iv
e 
Ce
ll 
G
ro
w
th
Scrambled_LowDensity
miR-145_LowDensity
100
1 2 3 4
Days
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SLC16A3 may also be a factor at play in this event. An additional miR-145 target candidate also 
implicated in breast cancer pathogenesis, integrin-linked kinase (ILK), has been shown to 
function as an oncogene and further, to be overexpressed in various cancers including breast.268, 
270
 ILK is a member of a plasma membrane-localized, multi-protein complex which transduces 
signaling from cellular integrins and growth factor receptors, such as receptor tyrosine kinases, 
to the actin cytoskeleton.270 Activation of ILK occurs in response to direct interaction with 
integrin or growth factor receptor proteins in a phosphatidylinositol 3-kinase (PI3K)-dependent 
manner, resulting in phosphorylation of downstream effectors; such as activation of protein 
kinase-B/AKT and inhibition of glycogen synthase kinase 3-beta (GSK3β), yielding a cellular 
phenotype that is resistant to anoikis and which exhibits increased cell survival and proliferation 
characteristics.268, 270 Furthermore, ILK has been shown to promote cell migration and invasion 
of tumor cells, as studies of small molecule inhibitors of ILK have resulted in inhibition of these 
activities.270, 272 Thus, further in the context of recently published data revealing decreased 
migratory activity in miR-145 expressing metastatic breast cancer cells254, 255, miR-145-mediated 
targeting of ILK may also be a factor underlying this event. Additionally, recent evidence 
revealed miR-145 expressing MDA-MB-231 cells exhibited significant remodeling of the actin 
cytoskeleton, resulting in reduced actin stress fiber and filopodia formation, supporting the 
observed decreased in migratory phenotype.254 ILK-mediated promotion of cell migration has 
also been shown to be accompanied by actin remodeling and increased formation of actin stress 
fibers, adding further support to the hypothesis that miR-145-mediated targeting of ILK may 
contribute to the decreases in cell migration. Interestingly however, the use of ILK-specific small 
molecule inhibitors or expression of a kinase deficient variant of ILK in MDA-MB-231 has been 
shown to induce significant anoikis in this cell line.268 These findings are inconsistent with recent 
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evidence indicating that miR-145 expressing MDA-MB-231 cells do not exhibit increases in 
apoptotic or growth inhibitory responses.253 This inconsistency may be due to concentration-
dependent effects of miR-145 on ILK versus alternate inhibitory strategies.268  However, it is 
possible that the panel of genes targeted by miR-145 produces a molecular context which results 
in inhibition of the migratory activity functions induced by ILK, but which does not impact the 
influence of ILK signaling on cell growth and survival. Furthermore, previous evidence has 
shown that the growth inhibitory activity of miR-145 is wt p53 or ERα-dependent, two 
characteristics which MDA-MB-231 and SKBR-3 cells lack. 
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Figure 16: Cell cycle analysis of MDA-145 vs. MDA-NEG cells. Data displayed 
is representative of sub-confluent cells harvested over a four day time-course. % 
cells observed for each cell cycle phases were averaged. Data is representative of 3 
independent replicates.  
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Confirmatory studies involving global proteomic analyses of SKB-145 cells transfected with a 
miR-145-specific anatgomiR vs. SKB-145 are summarized in (Table 3). In this context, proteins 
which were increased above log2 +0.25-fold change in SKB-145KD conditions were 
characterized for the presence of a miR-145 3’UTR “seed sequence”. Assessment of the 11 
mutually, differentially abundant miR-145 target candidates observed between MDA-145 and 
SKB-145 analyses revealed 2 proteins which exhibited a reversed expression profile in SKB-
145KD studies, SLC16A3 and VPS26A (Table 4, bolded). These results support initial 
observations of SLC16A3 and VPS26A as being targets of miR-145, and further that they may 
Figure 17: Wound healing analysis of MDA-145 vs. MDA-NEG cells. 
Wounded cells were imaged in 12-24 hour intervals. Data is representative of 
2 independent replicates.  
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represent candidates which are acutely sensitive to miR-145 levels as SKB-145KD cells 
exhibited only a 15% decrease in miR-145 levels versus SKB-145. 
 
Phenotypic analysis of growth, cell cycle and migration characteristics in MDA-MB-231 
cells stably expressing miR-145.  
Analysis of the impact of miR-145 on basal growth characteristics of MDA-MB-231 was 
achieved by comparative analysis of MDA-145 and MDA-NEG cell growth over a four day 
time-course utilizing an MTT cell proliferation assay (Fig 15). Results revealed that miR-145     
had no impact on the basal growth rate of MDA-MB-231 cells. These findings are further 
corroborated by cell cycle analysis of MDA-145 and MDA-NEG over a four day time-course 
which also revealed no significant variation in cell cycle profiles between these conditions (Fig 
16). These results have been corroborated by another group253, with further evidence, as 
aforementioned, indicating miR-145-mediated growth inhibition as occurring only in breast 
cancer cell lines expressing wt p53 or ERα.253 Assessment of the impact of miR-145 on 
migratory activity of MDA-MB-231 was achieved via comparison of MDA-NEG and MDA-145 
cells utilizing a wound healing assay over a 48 hour period (Figure 17). Results revealed a 
modest phenotype indicating impaired migratory ability in MDA-145 cells, with disorganization 
of cells at the leading edge of the wound at 16 hours and incomplete monolayer formation at 48 
hours post-wound initiation. Impaired migratory, as well as invasive and metastatic potential, 
have also recently been described in MDA-MB-231 cells stably expressing miR-145.254, 255 
Further, the impaired migratory phenotype in MDA-145 cells reported by Gotte et al. was more 
profound than we had observed and is likely due to the miR-145 expression levels in which they 
report in MDA-MB-231 versus our model system; which were over 10,000-fold higher than 
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control cells versus our model in which we achieved only a ~30-fold increase in miR-145 levels. 
These findings again indicate the regulatory impacts of miR-145 likely occur in a concentration-
dependent fashion.  
 
Conclusion 
These analyses have yielded a panel of experimentally observed miR-145 target candidates in 
two cell line models of breast cancer, MDA-MB-231 and SK-BR-3, and further revealed 11 
target candidates which were mutually observed between both analyses, suggesting these factors 
may be conserved regulatory targets. Mutually observed targets reveal modulation of proteins 
associated with cellular metabolism, mitochondrial function and molecular transport, further 
revealing two proteins which have previously been associated with breast cancer, SLC16A3 and 
ILK. The experimental design of this miR-145 target discovery platform was directed towards 
the identification of intact 3’UTR “seed” sequences for miR-145 to increase the confidence of 
target candidates observed. However, significant evidence has been shown that these seed 
regions tolerate mismatches, such as G:U base-pairing256, which has been observed in seed 
regions of validated miR-145 targets, such as c-myc251 or insulin-receptor substrate-1 (IRS-1)273. 
Further discovery of validated miR-145 targets will provide insights into the possible  “seed” and 
downstream binding characteristics which support effective miR-145 activity, offering evidence 
which will guide future target discovery efforts. When pairing target discovery and phenotypic 
data with previously published evidence of miR-145 activity in breast cancer cells, these 
analyses provide evidence to support that miR-145 activity is concentration-dependent. This 
observation is vital when considering the possible therapeutic utility of restoring miR-145 
expression in breast cancer cells, which has been proposed.254 In conclusion, these analyses 
79 
provide an ensemble of miR-145 regulatory targets in two cell line models of human breast 
cancer which warrant further investigation for their role in breast cancer pathogenesis. 
Furthermore, evidence is provided to support previous observations associated with the 
phenotypic modulation induced by miR-145 in metastatic breast cancer cells as well as the 
application of global, quantitative proteomic analyses as a strategy to elucidate the impact of 
microRNA function on the cellular transcriptome and proteome.  
4.0 CHAPTER 3: DIFFERENTIAL PROTEOMIC ANALYSIS OF LATE-STAGE AND 
RECURRENT BREAST CANCER FROM FORMALIN-FIXED PARAFFIN 
EMBEDDED TISSUES. 
Breast cancers exhibit a high degree of molecular heterogeneity, a characteristic that can 
confound the accurate determination of disease prognosis, thus more incisive tools are required 
to define the molecular characteristics underlying neoplastic progression as well as which 
provide greater insights into risk of disease recurrence.25, 26 In the context of protein-based 
prognostic biomarkers for breast cancer, determination of the ER, PR and HER2 status by 
immunohistochemical (IHC) analysis of patient tumor biopsies remains the gold standard for 
assessment of disease prognosis and provides the foundation for which patient treatment options 
are selected.46, 76 Further, profiling of the urokinase plasminogen activator (uPA)/plasminogen 
activator inhibitor (PAI-1) proteins by enzyme-linked immunosorbent assay (ELISA) in early-
stage breast cancer has been shown to highly correlate with disease prognosis with increased 
expression of either protein being associated with poor disease outcome and an elevated risk of 
disease recurrence.46, 76 Still, the performance of many protein-based biomarkers as prognostic 
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tools in breast cancer, such as biomarkers of cell proliferation, like Ki-67 (proliferating cell 
nuclear antigen, PCNA) or cyclin D, have been criticized due to significant inter-patient 
variability and inconsistent pathological scoring methodologies.76 Discovery of protein 
candidates that function to better discern stages of disease progression and provide insights into 
disease prognosis and recurrence risk would greatly aid in defining the facile molecular tools 
needed to achieve more confident diagnostic and prognostic assessments. 
 
One resource for the discovery of breast cancer biomarkers are formalin-fixed, paraffin 
embedded (FFPE) tissues.80, 123 Gene expression profiling in FFPE tissues has proven fruitful, 
but are often complicated by the impact of formalin fixation on nucleic acids as this can result in 
fragmentation and degradation of mRNA products due to the addition of monoethylol moieties to 
nucleotides and the formation of methylene-bridged, adenine dimers relative to mRNA products 
recovered from fresh tissue sources.125, 126 However, multiple investigations have demonstrated 
high concordance in proteins identified from fresh and FFPE tissues sources indicating that the 
impact of fixation on MS-based analysis of proteins derived from FFPE tissue as being 
minimal.123, 127  
 
Several comparative, global proteomic analyses of tumor samples derived from FFPE tissues 
have been performed 129, 131, 274, though few that have focused specifically on breast cancer.132  
We have undertaken a global proteomic analysis of pathologically-defined tumor regions 
obtained by LM from archival, FFPE tissues from twenty-five breast cancer patients presenting 
with stage 0, II and III disease at the time of diagnosis, with a subset of stage II patients 
exhibiting recurrent (R) disease after initial disease diagnosis. The goal of these analyses was to 
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identify protein abundance characteristics indicative of early to late-stage disease progression as 
well as of recurrent disease in breast cancer. Data analysis revealed 113 proteins that 
significantly differentiated patients diagnosed at early (stage 0, n=7) versus late-stage (stage III, 
n=9) disease and 42 proteins that significantly differentiated stage II patients that did (stage II R, 
n=5) or did not (stage II NR, n=4) exhibit recurrent disease. Verification of differentially 
abundant proteins was achieved via immunohistochemical (IHC) analyses of primary FFPE 
tissue samples for protein candidates from each stage comparison, i.e. thrombospondin-1 (TSP-
1) for stage 0 versus stage III disease and Protein DJ-1 (PARK7) for stage II NR versus stage II 
R. These data reveal differentially abundant proteins indicative of neoplastic progression and 
disease recurrence that provide insights into the molecular characteristics underlying breast 
cancer pathogenesis.  
 
Materials and Methods 
 
Breast cancer tissue sample preparation  
Twenty-five FFPE breast cancer patient tissue samples (Table 5) were sectioned onto LM slides 
(Director Slides, Expression Pathology Inc., Gaithersburg, MD) for tissue microdissection 
(LMD6000, Leica Microsystems, Bannockburn, IL). Disease recurrence in patients presenting 
with stage II disease was determined two years following initial diagnosis. Pathologically-
defined regions of cancerous epithelium were procured from all twenty-five patient samples and 
tryptic digests were prepared for global proteomic profiling utilizing the Liquid Tissue FFPE 
proteomic sample preparation kit (Expression Pathology, Inc., Gaithersburg, MD) as per the 
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manufacturer’s recommendations. Samples were re-suspended at a final concentration of 0.2 
ng/µL in 0.1% trifluoroacetic acid (TFA).    
 
Liquid chromatography-tandem mass spectrometry  
Total peptide digests were resolved by nanoflow reverse-phase liquid chromatography (Ultimate 
3000, Dionex Inc., Sunnyvale, CA) coupled online via electrospray ionization to a linear ion trap 
mass spectrometer (LTQ, ThermoFisher Scientific, Inc., San Jose, CA). Triplicate injections of 
1.2 µg of peptides derived from each patient tissue sample were resolved on a 100 µm i.d. by 360 
µm o.d. by 200 mm long fused silica capillary columns (Polymicro Technologies, Phoenix, AZ) 
slurry-packed in-house with 5 µm, 300 Å pore size C-18 silica-bonded stationary phase (Jupiter, 
Phenomenex, Torrance, CA). After sample injection, peptides were eluted from the column using 
a linear gradient of 2% mobile phase B (0.1% formic acid (FA) in acetonitrile to 40% mobile 
phase B over 125 min at a constant flow rate of 250 nL/min followed by a column wash 
consisting of 95% B for an additional 20 min at a constant flow rate of 400 nL/min. The LTQ 
MS was configured to collect broadband mass spectra (m/z 375-1800) from which the seven-
most abundant peptide molecular ions dynamically determined from the MS scan were selected 
for tandem MS using a relative CID energy of 35%. Dynamic exclusion was utilized to minimize 
redundant selection of peptides for CID. 
 
MS data analysis 
Peptide identifications were obtained by searching the LC-MS/MS data utilizing SEQUEST 
(BioWorks, v3.2, ThermoScientific) on a 72-node Beowulf cluster against a UniProt-derived 
human proteome database (version 10/08, 56,301 protein entries) obtained from the European 
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Bioinformatics Institute (EBI) using the following parameters: trypsin (KR); full enzymatic-
cleavage; two missed cleavages sites; 1.5 Da peptide mass tolerance peptide tolerance, 0.5 Da 
fragment ion tolerance and variable modifications for methionine oxidation (m/z 15.99492). 
Resulting peptide identifications were filtered according to specific SEQUEST scoring criteria: 
delta correlation (∆Cn) ≥ 0.08 and charge state dependent cross correlation (Xcorr) ≥ 1.9 for 
[M+H]1+, ≥ 2.2 for [M+2H]2+, and ≥ 3.5 for [M+3H]3+. These criteria resulted in a false 
discovery rate (FDR) of 5.84% for all peptides identified as determined by searching the entire 
data set against a decoy human database where the protein sequences were reversed.178 Protein 
abundance was derived by spectral counting (SC) and peptides whose sequences mapped to 
multiple protein isoforms were grouped as per the principle of parsimony.179 To determine 
statistically significant changes in protein abundance across patient samples by disease stage sub-
groups, a hierarchical supervised cluster analysis of peptides identified from stage 0 versus stage 
III and stage II NR disease recurrence (Stage II NR) versus stage II with disease recurrence 
(Stage II R) patient samples was performed in which the variance in total spectral count peptides 
identified was determined utilizing the Mann−Whitney rank-sum test (significance level p ≤ 
0.05, Fisher’s exact test) paired with the filter criteria requiring that 60% of the samples in a 
supervised group had a minimum peptide count of 2 or greater for a given protein. 
 
Bioinformatic analyses 
Uniprot accessions corresponding to significantly, differentially abundant proteins were mapped 
to HUGO (HGNC) gene symbols utilizing Ingenuity Pathway Analysis (IPA) (Ingenuity® 
Systems, www.ingenuity.com). Accessions that failed to map were converted to HGNC 
identifiers by manual inspection at www.uniprot.org and re-mapped to IPA to maximize protein 
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identifications available for downstream bioinformatic analyses; a unique HGNC designation for 
accession # P84243 from comparative stage II analysis could not be determined and was thus not 
utilized in downstream functional analysis. Functional analysis of significant protein lists were 
performed utilizing the “Core Analysis” function in IPA and inferred biofunctions exhibiting a p 
< 0.05 and a minimum of two associated proteins were considered significant. 
    
Immunohistochemical Verification 
Immunohistochemical verification (MDR Global Systems LLC, Windber, PA) was performed on 
primary FFPE tissue sections and antigen recovery was achieved utilizing the Dako PT Module 
(Dako, Denmark). Immunostaining was performed on a Dako autostainer and all slides were 
counterstained with hematoxylin and blued with 1% ammonia water.  Antibody conditions were  
as follow: 1: estrogen receptor (ER alpha, ERA), (clone 1D5/mouse, 1:200, Dako), 2: 
progesterone receptor (PGR), (clone PGR636/mouse, 1:400, Dako) 3: Her2/Herceptest, 
(polyclonal/rabbit, FDA guidelines, Dako) 4: Thrombospondin-1 (TSP-1), (1:50, clone 
A6.1/mouse, Abcam) and 5: Park7/DJ1, (1:800, polyclonal/goat, Abcam). 
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Diagnosis Patients (n) Age DCIS LCIS ILC IDC Comb/Other ER+ HER2+ Basal-like 
Stage 0 7 58 (± 11) 4 1 0 1 1 6 1 0 
Stage II NR 4 58 (± 12) 0 0 0 1 3 0 1 3 
Stage II R 5 56 (± 21) 1 0 0 2 2 0 2 3 
Stage III 9 62 (± 11) 0 0 4 4 1 6 0 3 
 
Table 5: Vital statistics of 25 patients presenting with discrete stages of disease.
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Figure 18: Significant, differentially abundant proteins identified in 
comparisons of stage 0 and stage III breast cancer patient tissue samples. 
Hierarchical supervised cluster analysis of stage 0 and stage III patient tissue 
data sets yielded 113 proteins which significantly differentiated these groups.  
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Results and Discussion 
 
Global proteomic analyses of pathologically-defined regions of cancerous epithelium, 
microdissected from FFPE-tissue samples derived from twenty-five breast cancer patients 
presenting with distinct stages of disease (Table 5) yielded 115,549 total peptide identifications 
(FDR of 5.84%) and 9,437 proteins identified by at least two peptides (Figure 18). Merits of 
analytical performance were monitored by comparing peptides identified between replicate 
injections for all 25 patient samples, revealing an average relative standard deviation (RSD) of 
9.5% (± 3.9%). Equivalency of protein digest input for LC-MS/MS analyses was determined by 
comparison of spectral count values for total peptides identified across all twenty-five patient 
samples where an RSD of 13.4 % was found, as well as for total peptides identified that 
corresponded to glyceraldehyde 3-phosphate dehydrogenase (GAPDH), a protein commonly 
utilized as a loading control for western blot analysis, revealing an RSD of 23.0% for this 
protein.180 These measures critically underpin the determination of significant, differentially 
abundant proteins by spectral counting without the need for normalization.  
 
Characterization of differentially abundant proteins between stage 0 and III breast cancer.  
 
Significant, differentially abundant proteins were established by hierarchical supervised cluster 
analysis in which at least 60% of the samples within a supervised group exhibited spectral count 
values of 2 or greater for a given protein of interest (Figures 19 and 23). Characterization of 
differential protein abundance indicative of early versus late-stage breast cancer was achieved by 
comparative analysis of proteomic data sets derived from stage 0 (n=7) and stage 3 (n=9) breast 
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cancer patient tissue samples (Figure 19). Results revealed a total of 113 proteins, 32 that were 
increased and 81 decreased in abundance in stage III vs. 0 disease, which significantly 
differentiated patients presenting with these disease stages. Stage III breast cancer is defined by 
Figure 19: Significant, differentially abundant proteins identified in 
comparisons of stage 0 and stage III breast cancer patient tissue samples. 
Hierarchical supervised cluster analysis of stage 0 and stage III patient tissue data 
sets yielded 113 proteins which significantly differentiated these groups.  
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evidence of tumor cell populations that have invaded from the primary tumor site and spread into 
regional breast lymph nodes, or by a primary tumor that has extended to the chest wall or skin.44, 
275, 276
  Locoregional invasion of tumor cells occurs as a product of phenotypic alterations, such 
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Figure 20: Differential abundance profile for Thrombospondin-1 (TSP-1) by 
spectral count peptides (A) and immunohistochemical verification (B) from 
Stage 0 and Stage III breast cancer patient tissue samples. A. Data reported 
indicates average peptides identified for TSP-1 by spectral count between Stage 0 
(n=7) and Stage III (n=9) samples. Results revealed a log2 +1.98-fold increased 
in TSP-1 in stage III versus stage 0 patients. B. Data reported indicates the 
percentage of patient tissues exhibiting an IHC score of 0+ or 1+ for TSP-1 in 
Stage 0 (n=6) and Stage III (n=9) samples. Results revealed 44% of stage III 
versus 0% of stage 0 patients exhibited an IHC score of 1+ for TSP-1.  
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as a loss of contact-inhibited growth and modulation of extracellular matrix (ECM) protein 
composition, which can be precipitated by selective pressures induced by the tumor 
microenvironment that accompany accelerated tumor growth, such as increased hypoxic and 
acidic conditions.9-11, 16, 18 Manual inspection of the 113 differentially abundant proteins observed 
between stage 0 and III patients revealed modulation of several extracellular matrix proteins in 
stage III disease, such as multiple collagen isoforms as well as biglycan (BGN, log2 +2.61-fold 
change in stage III versus stage 0 disease), mucin 5AC  (MUC5AC, log2 +1.32) and 
thrombospondin-1 (TSP1, log2 +1.98) (Figure 19 and Figure 20A and 20B – TSP-1 data). 
Among the differentially abundant collagen isoforms observed, the type I collagens, COL1A1 
(log2 +0.94) and COL1A2 (log2 +1.19), were found to be increased in abundance in stage III 
patients and corresponding mRNA for these factors has previously been shown to be 
overexpressed in invasive breast carcinoma.277 Increased deposition and aberrant cross-linking of 
collagen is associated with the development of invasive breast cancer, the result of which 
contributes to “stiffening” of the ECM and is a factor that has been shown to drive progression of 
in situ disease.278, 279 The ECM-localized proteoglycan BGN was observed as being increased in 
stage III patients and previous evidence has revealed BGN mRNA levels are increased with 
breast cancer disease progression, as evidenced by comparisons of patient-matched IDC versus 
DCIS breast cancer tissues.280 The ECM glycoprotein MUC5AC was also observed as being 
increased in stage III disease, and though this mucin isoform has been previously shown to be 
increased in cancerous versus normal breast tissues281 a lack of correlation between MUC5AC 
expression and other clinicopathological parameters utilized in breast cancer diagnostics, such as 
disease grade, revealed this factor to have weak prognostic value.282 Further, the ECM 
glycoprotein TSP-1 was observed as being increased in stage III patients and previous evidence 
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has indicated that TSP-1 levels are increased in breast cancer tissues as well as found at high 
levels in malignant breast secretions283-285 However, clinical assessment of TSP-1 expression in 
specific histological subytpes and stages of breast cancer disease progression have been 
ambiguous.286, 287 Increased TSP-1 expression is predominantly observed in breast tumor stroma 
A. B.
C. D.
Figure 21: Representative immunohistochemical (IHC) analysis of
Thrombospondin-1 (TSP-1) in stage 0 (A & B) versus stage III (C & D)
patient tissues. A: Hematoxylin and eosin staining of stage 0 patient tissue. B:
IHC staining for TSP-1 in corresponding stage 0 patient tissue. C: Hematoxylin
and eosin staining of stage III patient tissue. C: IHC staining for TSP-1 in
corresponding stage III patient tissue. Observed vacuolar staining pattern for TSP-
1 denoted by arrow.
D  
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and early studies of this phenomenon comparing invasive ductal carcinoma (IDC) and ductal 
carcinoma in situ (DCIS) breast cancer subytpes revealed TSP-1 levels were significantly higher 
in stromal tissues adjacent to invasive disease as well as in both tumor and stromal cell types in 
malignant versus normal breast tissues.287 Recent evidence characterizing TSP-1 expression in 
DCIS has shown that decreased TSP-1 levels in adjacent tumor stroma is associated with more 
aggressive disease characteristics, such as evidence of high histological grade and increased 
tissue necrosis, correlating with a poorer disease prognosis in these individuals.286 TSP-1 is an 
inhibitor of angiogenesis and exogenous expression of TSP-1 has been shown to elicit both anti-
tumorigenic and anti-angiogenic effects in breast cancer cell lines.283, 285 Assessment of TSP-1 
expression associated with microvessel density, a measure of angiogenesis, in breast cancer 
tissues revealed both positive and negative associations of TSP-1 with these features, findings 
that complicate defining a central role for TSP-1 in angiogenesis.283 We confirmed the increased 
abundance of TSP-1 in stage III patients observed by differential proteomic analysis (Figure 
20A) by IHC of TSP-1 in stage 0 (n=6) and stage III (n=9) patient tissue samples (Figure 20B 
and Figure 21) which revealed a complete lack of TSP-1 staining in stage 0 tissues relative to 
stage III tissues of which 44% exhibited an IHC score of 1+ (Figure 20B). Further, TSP-1 
staining in stage III tissues was observed as being predominantly localized to cellular vacuoles or 
intra-cytoplasmic lumina of tumor cell populations (Figure 21). Interestingly, IHC analysis of 
TSP-1 abundance in stage II patient tissues also revealed increases of TSP-1 in stage II R 
patients versus stage II NR, though this profile was not significantly observed in proteomic 
analyses. Our results therefore substantiate previous reports indicating that TSP-1 expression is 
increased with invasive breast cancer and provide evidence to support this abundance profile that 
indicate a higher risk for developing recurrent disease.           
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Figure 22: Significant, differentially abundant proteins identified in 
comparisons of stage 0 and stage III breast cancer patient tissue samples. Top 10 
significant biofunctions observed in proteins differentiating stage 0 and stage III 
patients. Data reported indicates significant p-values and mean number of proteins 
observed which clustered with a specific biofunction.  
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Analysis of functional biological characteristics amongst differentially abundant proteins 
between stage 0 and III breast cancer.  
Functional analysis of the 113 proteins differentiating stage 0 and stage III patients revealed the 
top ten significant biofunctions to be predominantly related to the overarching theme of cancer, 
specifically being associated with the regulation of tumorigenesis as well as being previously 
implicated in gastrointestinal cancer pathogenesis (Figure 2B). One significant biofunction 
category - namely “compaction of tumor cell lines" - was of interest as this cellular phenomenon 
is associated with the maintenance of intercellular interactions between tumor cells, an event that 
is disrupted in invasive and metastatic breast tumor cells.11, 288 This biofunction category 
contained three proteins, E-cadherin (CDH1, log2 -1.57 in stage III versus stage 0), alpha-catenin 
(CTNNA1, log2 -1.24) and beta-catenin (CTNNB1, log2 -2.56), all of which are core constituents 
of cellular adherens junctions that comprise plasma membrane-localized, multi-protein 
complexes which mediate intercellular adhesion and communication via direct interaction with 
the cellular actin cytoskeleton.11, 284 The formation of intercellular adherens junctions, which is 
facilitated through interaction of adjoining cadherin proteins, produces a contact inhibition signal 
that halts cell proliferation, the response to which is lost during cellular transformation.11 
Modulation of expression of CDH1, CTNNA1 and CTNNB1 are canonical characteristics of 
transformed mammary epithelial cells, with loss of CDH1 specifically being a hallmark of 
invasive and metastatic breast tumor cells, such as those that have undergone epithelial to 
mesenchymal transition, with this decrease further being found to correlate with a poor disease 
prognosis.11, 284, 289 Loss of both CTNNA1 and CTNNB1 have also been reported in breast 
carcinomas, particularly in invasive disease variants or as precursors to these subtypes.284, 290, 291 
Interestingly, loss of expression of CTNNB1 with disease progression in particular is 
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inconsistent with the oncogenic role CTNNB1 plays in the pathogenesis of a variety of cancers 
including breast.288 The canonical role of CTNNB1 is to function as a signaling intermediate 
between CDH1 and cellular actin at cellular adherens junctions.288 However, CTNNB1 can 
further function as a transcriptional co-factor, mediating translation of upstream signaling by the 
Wnt/Frizzled G-protein coupled receptor family via translocation to the nucleus and interaction 
with lymphoid enhancer factor/t-cell factor (LEF/TCF) transcription factors resulting in 
transcriptional activation of LEF/TCF gene targets, such as cyclin D1.288 Insights into the role of 
CTNNB1 dysregulation in cancer have emerged from studies of familial adenomatous polyposis, 
a heritable form of colorectal cancer that often occurs due to mutations in the tumor suppressor 
gene adenomatous polyposis coli (APC), a protein directly implicated in regulating CTNNB1 
stability.292, 293 APC functions as a cytoplasmic scaffolding protein that facilitates the targeting of 
CTNNB1 for ubiquitin-mediated proteolysis. 293 This is achieved through APC recruiting 
glycogen synthase kinase 3 beta (GSK3β) that directly phosphorylates cytoplasmic CTNNB1, 
targeting it for degradation.293 Loss of APC results in increased stability of CTNNB1 and 
increased CTNNB1-dependent transcriptional activity that drives cellular transformation.293 
Notably, we observed APC (log2 -1.1) abundance as being decreased in stage III versus stage 0 
disease. When pairing the observed decrease in CTNNB1 and APC abundance in stage III 
disease, a context is produced in which the diminished population of CTNNB1 may possess 
increased stability and thus function to further drive disease progression. Indeed, modulation of 
APC via mutation or via epigenetic mechanisms has been observed in invasive breast cancers.292-
294
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Characterization of differentially abundant proteins between stage II non-recurrent and 
recurrent breast cancer.  
Characterization of differential protein abundance in patients diagnosed with stage II disease that 
did (stage II R) or did not exhibit recurrent disease (stage II NR) two years following initial 
diagnosis was achieved by comparative analysis of proteomic data sets derived from stage II NR 
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Figure 23: Significant, differentially abundant proteins and subsequent 
functional characteristics identified in comparisons of stage II NR and stage 
II R breast cancer patient tissue samples. Hierarchical Supervised cluster 
analysis of stage II NR and stage II R patient tissue data sets yielded 42 proteins 
which significantly differentiated these groups.  
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(n=4) and stage II R (n=5) patient tissue samples (Figure 23). Results revealed a total of 42 
proteins, 31 that were increased and 11 decreased in abundance, which significantly 
differentiated stage II NR versus II R patients (Figure 23). Stage II breast cancer is defined as 
Figure 24: Differential abundance profile for Protein DJ-1 (PARK7) by 
spectral count peptides (A) and immunohistochemical verification (B) from 
Stage II NR and Stage II R breast cancer patient tissue samples. A. Data 
reported indicates average peptides identified for PARK7 by spectral count 
between Stage II NR (n=4) and Stage II R (n=5) samples. Results revealed a log2 -
1.9-fold decrease in PARK7 in stage II R versus stage II NR patients. B. Data 
reported indicates the percentage of patient tissues exhibiting an IHC score of 1+ 
or 2+ for PARK7 in Stage II NR (n=4) and Stage II R (n=5) samples. Results 
revealed 20% of stage II R versus 50% of stage II NR patients exhibited an IHC 
score of 2+ for PARK7.  
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evidence of a primary tumor ranging from 2 to 5.0 cm in size with or without locoregional 
invasion of tumor cells to as many as three axillary breast lymph nodes.44, 276 The mechanisms 
 underlying disease recurrence in breast cancer are diverse and include the development of 
acquired resistance in tumor cells to adjuvant therapeutics, such as trastuzumab (herceptin), a 
monoclonal antibody-based therapeutic utilized in the treatment of HER2+ breast cancer295, as 
well as due to the impact of increased immune cell signaling following surgical treatment of 
breast cancer, which has been shown to suppress immune cell function and produce a signaling 
environment that can promote the growth of residual disease or of nascent tumor cell 
A. B.
C. D.
Figure 25: Representative immunohistochemical (IHC) analysis of 
Protein DJ-1 (PARK7) in stage II NR (A & B) versus stage II R (C & D) 
patient tissues. A: Hematoxylin and eosin staining of stage II NR patient 
tissue. B: IHC staining for PARK7 in corresponding stage II NR patient 
tissue. C: Hematoxylin and eosin staining of stage II R patient tissue. D: IHC 
staining for PARK7 in corresponding stage II R patient tissue.  
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populations. 296, 297 Of the 42 proteins that differentiated stage II NR and II R patients, 
adenosylhomocysteinase (AHCY, log2 +2.55 fold in stage II R vs. II NR) was found to be 
significantly increased in patients exhibiting recurrent disease, a protein that has previously been 
shown to be increased in cancerous versus normal breast tissues.298 AHCY catalyzes the 
conversion of S-adenosylhomocysteine to homocysteine and elevated homocysteine levels have 
been associated with increased DNA hypomethylation and subsequent aberrant gene expression 
that has been related to the acquisition of a drug resistant phenotype.299, 300 Indeed, incubation of 
a human cell line model of ER+ breast cancer, MCF-7, with homocysteine resulted in resistance 
to the chemotherapeutic agents doxorubicin and cisplatin as well as upregulation of drug 
resistance markers.300 The increased abundance of AHCY in stage II R patient tissues may thus 
support increased homocysteine production resulting in tumor cell phenotypes that are more 
refractory to chemotherapeutic treatment. Further assessment of proteins differentiating stage II 
NR and II R patients revealed protein DJ-1 (PARK7, log2 -1.91) as being decreased in stage II R 
tissues, a factor that is commonly mutated in early-onset, recessive Parkinson’s disease and 
shown to function as a neuroprotectant against oxidative stress in this context and has further 
been shown to function as an oncogene in various cancer subtypes including breast.301, 302 
Specifically, PARK7 has been observed as being increased in breast cancer tissues and further 
found at increased levels in serum derived from breast cancer patients, a finding that has lead to 
the proposal of PARK7 as a prognostic marker for breast cancer.302-304 Investigations into the 
oncogenic role of PARK7 in lymph node-negative breast cancer tissues has revealed expression 
of this factor to correlate with increased levels of phosphorylated PKB/Akt protein, a 
downstream signaling intermediate of the PI3K pathway that is aberrantly activated in tumor 
cells resulting in an increased cell survival phenotype, as well as decreased levels of the tumor 
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suppressor PTEN, an antagonist of PI3K signaling and a factor that PARK7 has been shown to 
directly suppress.302 However, in instances of breast cancer tissues that exhibited non-
phosphorylated PKB/Akt proteins, evidence of PARK7 expression was less frequent, suggesting 
alternative signaling pathways may be emphasized in these contexts.302 The observed decrease of 
PARK7 abundance in stage II R vs. stage II NR breast cancer tissues, a profile that was also 
observed as significant in comparisons of stage 0 and stage III breast cancer (log2 -1.44), 
supports this hypothesis. We confirmed the decreased abundance of PARK7 in stage II R 
patients observed by differential proteomics (Figure 24A) via IHC analysis of PARK7 in stage II 
NR (n=4) and stage II R (n=5) patient tissue samples (Figure 24B and Figure 25) that revealed an 
equal distribution of stage II NR patients exhibiting a score of 1+ and 2+ for PARK7 and 80% of 
stage II R patients exhibiting a 1+ score versus 20% that were 2+ for PARK7, verifying our 
discovery LC-MS/MS data. However, IHC confirmatory studies for decreased PARK7 
abundance in stage III versus stage 0 patients only modestly recapitulated the LC-MS/MS 
observations (44.4% of stage III samples indicating a +2 score versus 55.5% of stage 0 samples), 
indicating this abundance profile may be more specific for stage II breast tumor cells with the 
capacity to produce recurrent disease.       
 
Analysis of functional biological characteristics amongst differentially abundant proteins 
between non-recurrent and recurrent stage II breast cancer.  
 
Functional analysis of proteins differentiating recurrence in stage II patients revealed the top ten 
significant biofunctions to be related to various functional themes, including neurodegenerative 
(dementia and tauopathy) and inflammatory diseases (rheumatoid arthritis and connective tissue 
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disorders) as well modulation of metabolic functions, such as uptake of calcium, experimentally-
induced diabetes and glycolysis of cells (Figure 26). One candidate of interest, being increased in 
stage II R patients versus II NR, was insulin receptor substrate-1 (IRS-1, log2 +2.14) that was 
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Figure 26: Significant, differentially abundant proteins and subsequent
functional characteristics identified in comparisons of stage II NR and
stage II R breast cancer patient tissue samples. Top 10 significant
biofunctions observed in proteins differentiating stage II NR and stage II R
patients. Data reported indicates significant p-values and mean number of
proteins observed which clustered with a specific biofunction.
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further associated with five of the top ten significant biofunctions, i.e. skeletal and muscular 
disorder, hematological disorder, connective tissue disorder, uptake of calcium and rheumatoid 
arthritis. IRS-1 functions as a scaffolding protein and signaling intermediate for the insulin-like 
growth factor-1 receptor signaling cascade and has been implicated in the pathogenesis of 
several cancers including breast.305, 306 IRS-1 has been shown to function as an oncogene in 
breast cancer, being associated with regulation of cell proliferation from gain and loss-of-
function analyses in cell line models of breast cancer as well as transgenic murine models.305, 306 
Assessment of IRS-1 expression in clinical breast cancer tissues has revealed ambiguous 
abundance profiles for this factor, with evidence of both increased and decreased levels being 
associated with breast cancer disease progression.305, 306 Interestingly, a study addressing the 
prognostic utility of assessing IRS-1 abundance in clinical breast cancer tissues revealed that 
higher levels correlated with an increased risk of disease recurrence following surgical 
intervention.306, 307 Indeed, the increased abundance profile we observe for IRS-1 in stage II R 
versus stage II NR patients supports these observations and provides provocative evidence that 
assessment of IRS-1 abundance may provide prognostic value in assessing disease recurrence 
risk.           
 
Conclusion 
A comparative, global proteomic analysis of pathologically-defined regions of cancerous 
epithelium, laser microdissected from FFPE-tissue samples derived from twenty-five breast 
cancer patients at distinct stages of disease progression revealed differentially abundant proteins 
indicative of disease stage as well provided functional insights into disease biology underlying in 
situ breast cancer, such as the coordinate modulation of CTNNB1 abundance and related 
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regulatory machinery, i.e. decreased APC abundance, with progression towards stage III disease 
and the increase in IRS-1 abundance in stage II R patient tissues that experienced disease 
recurrence. These data provide robustly, differentially abundant protein candidates that warrant 
further validation for potential prognostic and predictive power as diagnostic tools in breast 
cancer. Verification by IHC analysis of primary breast cancer tissues for two candidates derived 
from these studies support this suggestion, confirming of the observed increase of TSP-1 
abundance and loss of PARK7 abundance in later stage disease (stage III) and in tissues derived 
from patients exhibiting recurrent disease (stage II R) initially observed by proteomic analysis, 
respectively. These data provide evidence to support the utility of FFPE tissues as a robust 
resource for retrospective biomarker studies and functional analyses utilizing MS-based 
proteomics workflows. Further, these data reveal several provocative protein candidates 
indicative of disease stage and recurrence that warrant continued investigation for their 
diagnostic utility and biological relevance in breast cancer pathogenesis. 
5.0 CHAPTER 4: DIFFERENTIAL PROTEOMICS ANALYSIS OF LYMPH-NODE 
METASTASIS IN ESTROGEN-RECEPTOR POSITIVE BREAST CANCER FROM 
FORMALIN-FIXED, PARAFFIN EMBEDDED TISSUES 
Estrogen receptor positive (ER+) breast cancer, also known as luminal breast cancer, is 
characterized by expression of ER as well as variable levels of progesterone receptor (PR) and 
the HER2 growth factor receptor.26, 33, 37, 39, 308 The expression characteristics of these latter 
proteins comprise the basis for further sub-classification, of which there are currently three 
recognized categories; luminal-A, luminal-B and luminal-C (Table 1). 33, 37, 39, 308 A luminal 
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breast cancer diagnosis is associated with better overall survival and prognosis relative to 
HER2+ or basal-like breast cancer subtypes, with luminal-A in particular as exhibiting the 
highest patient outcome relative to the luminal-B subtype due in part to luminal-A cancers 
expressing more ER-associated genes and fewer genes associated with cellular proliferation and, 
further, due to luminal-A cancers tending to be of lower grade than luminal-B.39, 308, 309 
Irrespective of the specific molecular breast cancer subtype identified at the time of diagnosis, 
evidence of locoregional invasion of primary tumor cells, such as into axillary or sentinel lymph 
nodes (LN) of the breast, correlates with a poorer disease prognosis overall.310 Lymph node 
involvement is commonly established by clinicopathological analyses which include the 
utilization of axillary ultrasound and ultrasound guided fine-needle aspiration cytology, as well 
as by characterization of disseminated tumor cell populations in biopsied LN tissues by 
pathological analysis.44, 311, 312 However, even with these diagnostic strategies in place, evidence 
of metastasis has been reported in up to 50% of individuals which initially present with apparent 
localized disease that has further been observed in 30% of individuals diagnosed with disease 
lacking apparent LN involvement, indicating that current methodologies lack the sufficient 
sensitivity needed to identify invasive disease characteristics at the outset of diagnosis.311 
Though the discovery and investigation of biomarkers directed towards the identification of LN 
disseminated tumor cells as well as which identify characteristics of breast tumor cells capable of 
LN invasion have been described, none of these candidates have been adopted into regular 
clinical use.311, 313, 314  
 
Thus, as luminal breast cancers represent the most commonly diagnosed clinical subtype of 
breast cancer, the identification of patients presenting with more aggressive disease 
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characteristics amongst this population, such as those exhibiting locoregional / LN invasion, may 
provide a basis in which to consider more aggressive therapeutic options for these individuals, 
such as treatment with ER-specific endocrine therapy, such as the ER antagonist tamoxifen, or 
aromatase inhibitors, an enzyme responsible for estrogen synthesis.39, 315 We therefore undertook 
a global proteomic analysis of pathologically defined regions of tumor epithelium derived from 
archival, formalin-fixed paraffin-embedded (FFPE) tissues obtained from a large cohort of ER+ 
breast cancer patients (n=35) which did (n=16) or did not (n=19) exhibit LN involvement by 
pathological analysis with the goal of identifying protein abundance characteristics which 
significantly differentiated luminal-type breast cancer tissues which have or have not undergone 
LN invasion. Results revealed 7 proteins which significantly differentiated these subgroups, two 
of which (ARL6IP5, log2 -1.07 in LN+ versus LN- disease) and RNA-binding protein 39 
(RBM39, log2 + 0.66) have been previously implicated in estrogen signaling in breast cancer. 
Validation efforts of these candidates by immunohistochemical analysis utilizing a tissue 
microarray of ER+, LN- and LN+ breast cancer tissues are currently underway.   
 
Materials and Methods 
 
Breast cancer tissue sample preparation 
Pathologically-defined tumor regions from seventy-five formalin-fixed paraffin-embedded 
(FFPE) breast cancer patient tissue samples derived from patients with ER+ or ER- breast 
cancers with (LN+) or without (LN-) lymph node metastasis were processed for global 
proteomic analysis (Dr. Rohit Bhargava, Department of Pathology, Magee Womens Hospital. 
Pittsburgh, PA). Processing entailed de-parrafinization of tissue sections via successive 5.0 min 
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incubations in Xylenes followed by a dehydration and wash regimen consisting of 30 s in 100% 
ethanol (EtOH), 30 sec. in 95% EtOH, 30 sec. in 70% EtOH and 30 sec. in H2O. Sections were 
lightly stained in Harris hematoxylin for 30 s and washed for 1.0 min in tap water, dehydrated 
for 30 s in 95% EtOH and air dried for 10 min. Defined regions were then manually scraped 
from an average of three slides per patient and pooled into 200 µL of 80 mM ammonium 
bicarbonate (AMB) and 20 % acetonitrile (ACN). Samples underwent two freeze-thaw cycles 
before being incubated at 95 ºC for 1 hr followed by 65 ºC for 2 h. 1.0 µg of porcine sequencing 
grade modified trypsin (Promega, Madison, WI) was then added to each sample followed by 
incubation at 37 ºC overnight. Samples were then briefly lyophilized to remove ambient ACN, 
centrifuged and total peptide concentrations were determined from resulting supernatants 
utilizing the bicinchoninic assay (BCA) and a protein standard curve derived from a diluted stock 
of 2.0 µg/mL α-casein (Sigma Aldrich). Samples which yielded at least 3.0 µg of peptide product 
(total: n = 48, i.e. ER+ (n = 35) ER- (n = 13) were utilized for downstream LC-MS analyses and 
were lyophilized and re-suspended to a final concentration of 0.1 µg/µL in 0.1% TFA.                
 
Liquid chromatography-tandem mass spectrometry analyses  
Peptide digests were resolved by nanoflow reverse-phase liquid chromatography (Ultimate 3000, 
Dionex Inc., Sunnyvale, CA) coupled online via electrospray ionization to a hybrid linear ion 
trap-Orbitrap Velos mass spectrometer (LTQ-Orbitrap Velos, ThermoFisher Scientific, Inc., San 
Jose, CA). Quadruplicate injections of 5 µL of peptide extracts were resolved on 100 µm i.d. by 
360 µm o.d. by 200 mm long fused silica capillary columns (Polymicro Technologies, Phoenix, 
AZ) slurry-packed in-house with 5 µm, 300 Å pore size C-18 silica-bonded stationary phase 
(Jupiter, Phenomenex, Torrance, CA). After sample injection, peptides were eluted from the 
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column using a linear gradient of 2% mobile phase B (0.1% FA in ACN) to 40% mobile phase B 
over 125 min at a constant flow rate of 200 nL/min followed by a column wash consisting of 
95% B for an additional 30 min at a constant flow rate of 400 nL/min. The LTQ-Orbitrap Velos 
MS was configured to collect high resolution (R=60,000 at m/z 400) broadband mass spectra 
(m/z 375-1800) from which the twenty-most abundant peptide molecular ions dynamically 
determined from the MS scan were selected for tandem MS using a relative CID energy of 35%. 
Dynamic exclusion was utilized to minimize redundant selection of peptides for CID.  
 
Peptide Identification and Spectral Count Analysis 
Peptide identifications were obtained by searching the LC-MS/MS data utilizing SEQUEST 
(BioWorks, v3.2, ThermoScientific) on a 72-node Beowulf cluster against a UniProt-derived 
human proteome database (version 6/10) obtained from the European Bioinformatics Institute 
(EBI) using the following parameters: trypsin (KR); full enzymatic-cleavage; two missed 
cleavages sites; 20 ppm peptide mass tolerance peptide tolerance, 0.5 amu fragment ion 
tolerance; and variable modifications for methionine oxidation (m/z 15.99492). Resulting peptide 
identifications were filtered according to specific SEQUEST scoring criteria: delta correlation 
(∆Cn) ≥ 0.08 and charge state dependent cross correlation (Xcorr) ≥ 1.9 for [M+H]1+, ≥ 2.2 for 
[M+2H]2+, and ≥ 3.5 for [M+3H]3+. To determine statistically significant changes in protein 
abundance across ER+ patient samples (n=35), a hierarchical supervised cluster analysis of 
peptides identified from ER+/ LN- (n=19) versus ER+/ LN+ (n=16) samples was performed in 
which the variance in total spectral count peptides identified was determined utilizing the 
Mann−Whitney rank-sum test (significance level p ≤ 0.05, Fisher’s exact test) paired with the 
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filter criteria requiring that 50% of the samples in a supervised group had a minimum peptide 
count of 2 or greater for a given protein. 
Results and Discussion: 
 
Global proteomic analyses of pathologically-defined regions of cancerous epithelium scraped 
from FFPE-tissue samples derived from forty-eight ER+ breast cancer patients (n=35) and ER- 
(n=13) disease yielded 19,947 total peptide identifications (Fig 27). Merits of analytical 
performance were monitored by comparing peptides identified between replicate injections for 
all forty-eight patient samples, revealing an average relative standard deviation (RSD) of 5.3% 
(± 5.0%) (Fig 28A). Equivalency of protein digest input for LC-MS/MS analyses was 
Figure 27: Analytical workflow utilized for differential proteomic 
analysis of ER+ formalin-fixed paraffin embedded (FFPE) primary 
breast cancer tissues. 
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determined by comparison of spectral count values for total peptides identified, indicating that an 
average of 1456 (± 417) peptide identifications was achieved across all forty- eight patient 
samples (RSD of 28.7%) (Figure 28B). Compilation of these results revealed an average of 528 
(± 128) proteins was identified by at least two peptides across all samples analyzed (RSD of 
24.3%). These measures critically underpin the determination of significant, differentially 
abundant proteins by spectral counting without the need for normalization. 
Figure 28: Metric of LC-MS performance during analysis of 48 patient samples. 
(A): Assessment of peptides identified between LC-MS/MS technical replicates 
revealed a mean RSD of 5.3% (± 5.0) across data set. (B): Average peptides identified 
for 48 patient tissue samples analyzed in quadruplicate over a ~6-week week period. 
Assessment of peptides identified across data set revealed a 28.7 % RSD in total 
peptides identified.   
 
0
500
1000
1500
2000
2500
3000
1 4 12 18 21 22 23 25 26 31 33 34 35 36 37 38 39 40 41 44 46 48 49 52 55 56 57 60 70 73 74 75 83 84 85 86 88 92 93 96 29 30 61 62 97 98 99
P
e
p
ti
d
e
 I
D
s
Patient
0
2
4
6
8
10
12
14
1 4 12 18 21 22 23 25 26 31 33 34 35 36 37 38 39 40 41 44 46 48 49 52 55 56 57 60 70 73 74 75 83 84 85 86 88 92 93 96 29 30 61 62 97 98 99
R
S
D
 (
%
)
Patient
A
B
109 
 
Characterization of differentially abundant proteins in ER+ patients with (LN+) or without 
(LN-) Lymph Node Metastasis.  
 
Significant, differentially abundant proteins were established by hierarchical supervised cluster 
analysis of ER+/ LN+ (n=16) or ER+/ LN- (n=19) proteomic data sets in which at least 50% of 
the samples within a supervised group exhibited spectral count values of 2 or greater for a given 
LN – (n=19)               LN + (n=16)
DMXL1
RMB39
ARL6IP5
ANXA11
HSPA1L
PSME1
PSMD1
Figure 29: Hierarchical supervised cluster analysis of proteomic analysis derived 
from 35 ER+ patient tissue samples ± LN metastasis: Cluster analysis was performed 
on total spectral count peptides utilizing the Mann−Whitney rank-sum test (significance 
level p ≤ 0.05, Fisher’s exact test) paired with the filter criteria requiring that 50% of the 
samples in a supervised group had a minimum peptide count of 2 or greater for a given 
protein. Results revealed a total of 7 proteins which significantly differentiated these 
groups by this criteria.  
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protein of interest (Fig 29). Results revealed 7 proteins which significantly differentiated these 
two sample groups (Table 6). Among these seven candidates, two proteins have previously been 
implicated in estrogen signaling in breast cancer, ADP-ribosylation-like factor 6 interacting 
protein 5 (ARL6IP5, log2 -1.07 in LN+ versus LN- disease)316 and RNA-binding motif protein 
39 (RBM39, log2 + 0.66).317, 318  
 
ARL6IP5, also known as JWA, is a microtubule-localized cytoskeletal protein that has been 
implicated in estrogen signaling as treatment of an ER+ human breast cancer cell line, MCF7, 
with fenvalerate, a pyrethroid insecticide shown to possess estrogenic activity, resulted in a dose-
dependent decrease in ARL6IP5 expression and a coordinate increase in cell proliferation.316   
Additional analyses of ARL6IP5 function have revealed this protein plays a regulatory role in 
cellular differentiation and apoptosis signaling and has been shown to be induced in response to 
cellular stressors, such as heat shock and oxidative stress, in a variety of cellular systems.319-321 
In the context of oxidative stress, ARL6IP5 has been shown to function as a protectant against 
benzo[a]pyrene, an environmental carcinogen, and H2O2-induced DNA damage in NIH-3T3 
fibroblast cells and further has been shown to be induced in MCF7 cells in response to H2O2 
treatment 320, 322, 323 Furthermore, recent evidence investigating this phenomenon has revealed 
that oxidative stress-induced ARL6IP5 promotes expression of XRCC1, a key DNA repair 
mediator associated with the base excision repair pathway, being further shown to complex with 
this protein at single-strand break sites in DNA as well as promote stabilization of XRCC1 
through the prevention of ubiquitin-mediated proteolysis.22 Interestingly, an additional function 
for ARL6IP5 has revealed this factor to be involved in regulation of cell migration, as loss of 
ARL6IP5 expression has been shown to greatly increase cell migratory characteristics of several 
111 
cancer cell lines including HeLa cells, B16 melanoma cells as well as HCCLM3 hepatocellular 
carcinoma cells.319 Assessment of these findings in the context of the observed decrease of 
ARL6IP5 abundance in LN+ versus LN- disease in our analysis, breast cancer cell types 
comprising ER+/LN+ disease may support a more robust response to estrogen leading to loss of 
ARL6IP5 versus ER+/LN- cells, thus resulting in an increase in cell migratory activity as well as 
impaired DNA repair capabilities which may promote the development of more aberrant and 
aggressive tumor cell types.  
 
RBM39, also known as CAPER, is a nuclear-localized factor that has been observed as being 
associated with spliceosome complexes and further to function as a specific transcriptional co-
activator for AP-1, ER-α and ER-β.317  RBM39 has been shown to directly interact with ER 
isoforms and to promote transcription of genes containing estrogen promoter response elements 
in response to exogenous treatment with E2 estradiol.317 Further analysis of mammary epithelia 
HGNC ID Protein Name
LN+ vs. LN-
Log2 Fold-Change 
Cellular 
Localization
Functional 
Type
ANXA11 annexin A11 -1.261 Nucleus other
ARL6IP5 ADP-ribosylation-like factor 6 interacting protein 5 -1.074 Cytoplasm other
DMXL1 Dmx-like 1 0.499 unknown other
HSPA1L heat shock 70kDa protein 1-like -0.613 Cytoplasm other
PSMD1
proteasome (prosome, macropain) 26S subunit, non-
ATPase, 1 -0.624 Cytoplasm other
PSME1
proteasome (prosome, macropain) activator subunit 1 
(PA28 alpha) -1.004 Cytoplasm other
RBM39 RNA binding motif protein 39 0.663 Nucleus
transcription 
regulator
Table 6: Significant proteins differentiating ER+/LN+ and ER+/LN- breast cancer 
tissues: Seven proteins identified which significantly differentiated ER+/LN+ and ER+/LN- 
groups. HGNC ID’s for proteins previously implication in estrogen signaling in breast cancer 
are in bold.  
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derived from transgenic mice homozygous null for caveolin-1, a plasma membrane-bound 
scaffolding protein that has been shown to be exclusively mutated in ER-α human breast cancers, 
revealed increased expression of RBM39 protein in these tissues which were further hyper-
responsive to exogenous estrogen relative to wild-type controls.318 Our observed increase in 
RBM39 abundance in LN+ versus LN- patients therefore supports the aforementioned 
hypothesis that ER+/LN+ breast tumor cell types may be more responsive to estrogen versus 
ER+/LN- cells. These observed differential abundance profiles for ARL6IP5 and RBM39 in 
LN+ versus LN- disease may thus produce a molecular context which supports more aggressive 
tendencies which translate to greater invasive potential.      
 
Conclusion 
 
These analyses have yielded a panel of seven differentially abundant proteins which significantly 
differentiated a large cohort of ER+ breast cancer patients presenting with or without lymph node 
metastasis. Further inspection of these results revealed two proteins, ARL6IP5 and RBM39, 
which have been previously implicated in estrogen signaling in breast cancer that exhibit an 
abundance profile which supports that ER+/LN+ breast tumor cells may have an increased 
capacity to respond to estrogen and thus may be a factor underlying the invasive characteristics 
exhibited by these cell types. Validation efforts of these candidates by immunohistochemical 
analysis utilizing a tissue microarray of ER+, LN- and LN+ breast cancer tissues are currently 
underway.    
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6.0: SUMMARY AND CONCLUSIONS 
 
The molecular heterogeneity of breast cancer underscores the benefits to be gained from analysis 
of this disease utilizing high-throughput proteomic analyses. This dissertation details the 
investigations of key subjects in breast cancer biology focused on the characterization of 
endogenous and experimentally-induced disease biology characteristics utilizing the application 
of LC-MS based proteomic analyses of both in vitro models of breast cancer as well as primary 
clinical samples. 
 
Data is presented which describes a combined global and functional proteomic strategy to 
discern governing functional roles for mutually, differentially abundant proteins which are 
observed across three tumorigenic cell lines models of human breast cancer corresponding to the 
most common molecular subtypes of disease clinically encountered, ER+, HER+ and basal-like 
disease, relative to a non-transformed model cell line of normal mammary epithelium. Though 
microarray evidence has revealed that breast tumor cells bearing these discrete hormone and 
growth factors receptor profiles exhibit subtype-specific gene expression signatures, observations 
of a mutual population of proteins exhibiting virtually identical abundance trends across these 
three subtypes of breast cancer indicates that there are central molecular characteristics which are 
conserved across breast cancer cells which may represent core characteristics of disease biology 
underlying these systems. Further functional analysis revealed a predominance of differentially 
abundant proteins associated with the regulation of cell spreading, with further analysis 
indicating many of these pro-cell spreading factors being lost across all tumorigenic breast 
cancer cells. Protein network analysis of these mutual candidates revealed a central factor 
associated with regulation of cell spreading , further known to be constitutively active in breast 
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cancer cells, focal adhesion kinase (FAK), as being associated with several of these dysregulated 
cell spreading-associated factors as well as other mutually dysregulated candidates which have 
been shown to inhibit expression of activity of FAK in other cell types and cancer disease 
pathologies. As FAK has been shown to play an integral role in maintaining characteristics of 
breast tumor cell tumorigenicity, these data revealed several targets which warrant further 
investigation for their role in regulating FAK in breast cancer. Further data is provided detailing 
a facile workflow towards the elucidation of functional biological characteristics in complex 
proteome data sets, an area of growing interest in proteomic research. Further analyses are 
described which focus on the fairly novel topic of applying proteomic analysis to the discovery 
of microRNA targets, a research area which has exploded in the last decade with the discovery of 
this previously unknown post-transcriptional gene regulatory mechanism. Investigation into this 
subject has revealed the parameters governing microRNA-mediated gene targeting to be 
complex, such as the tolerance of variable base-pairing within microRNA-target duplex “seed” 
regions as well as the impact of RNA secondary structure on microRNA target site accessibility. 
Further, the clear delineation of the characteristics which govern regulation of microRNA-
mediated target degradation or translational repression have yet to be established. The efforts 
described herein were two-fold in that they were focused on 1) devising a microRNA target 
discovery platform utilizing proteomic analysis and further 2) towards the elucidation of 
experimentally observed targets of a microRNA which has been implicated in breast cancer 
pathogenesis, miR-145. The results of these efforts yielded a proteomics-based microRNA target 
discovery workflow focused on the identification of high confidence microRNA targets bearing 
intact 3’UTR “seed” regions as well as the identification of a panel of microRNA target 
candidates which were mutually regulated across two cell line models of metastatic breast 
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cancer, MDA and SKB cells. Comparative analysis of the robustly different levels of miR-145 
achieved upon restoration of expression in MDA and SKB cells with the prevalence of miR-145 
“seed” containing protein targets observed as decreased in abundance in response to miR-145 
provided evidence to support the hypothesis that microRNA activity is concentration dependent. 
This is a vital issue to consider in the context of therapeutic microRNA restoration or silencing 
strategies which have been proposed for various disease associated microRNAs. Further 
investigation of microRNA activity which attempts to mimic physiologically observed levels of a 
microRNA in endogenous tissue would provide a better experimental context in which to 
investigate microRNA function as well as which would provide expression benchmarks for 
which to achieve in gene therapy strategies aimed at modulating microRNA levels.                     
 
Data is further described which focuses on the global proteomic analysis of clinical breast cancer 
tissues towards the identification of protein characteristics representative of disease stage as well 
as indicative of recurrent disease. As high-throughput sample analysis is suited to proteomic 
workflows, the opportunity to perform large-scale analysis of clinical samples is an attractive 
capability towards the discovery of conserved protein abundance characteristics which are 
indicative of in situ disease. Further, the ability to draw upon basic research findings describing 
the roles of different protein candidates in various cellular systems and disease processes enables 
the elucidation of functional biological characteristics from large-scale proteome analyses which 
may better clarify disease and tissue-specific molecular processes. These data further add to the 
growing arsenal of proteomic analyses utilizing formalin-fixed, paraffin embedded (FFPE) 
tissues samples for retrospective biomarker investigations. The large archives of FFPE tissue 
banks world-wide represent an excellent resource in which to obtain large numbers of clinical 
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samples for analysis which will add sufficient power to observations made that may more readily 
expedite findings to clinical applications. The results of the FFPE proteomic analyses described 
herein adds further evidence to support the utility of these sample sources for retrospective 
proteomic investigations. This was evidenced in comparisons of early and late-stage breast 
cancer revealed differential abundance profiles for several proteins are well established in breast 
cancer pathogenesis, such as a loss of CDH1 (E-Cadherin) as well as modulation of CTNNB1 
(beta-catenin) and CTNNB1 regulatory machinery, i.e. APC (adenamatous polyposis coli). 
Further, the verification of the abundance profiles for two novel factors associated with different 
disease stage and recurrent disease characteristics by immunohistochemical analysis, TSP-1 
(thrombospondin) and PARK7 (Protein DJ-1) adds further credence to the utility of these sample 
sources for proteomic study. Lastly, the identification of factors differentially abundant in ER+ 
breast cancer tissues with and without lymph node (LN) metastasis, which have been previously 
implicated in estrogen signaling and further which exhibited abundance profiles supporting the 
hypothesis that ER+ breast tumor cells capable of achieving LN metastasis may be more 
responsive to estrogen signaling, further adds support to the observations made utilizing these 
sample sources. The differential abundance profiles for proteins associated with disease stage as 
well as indicative of recurrent disease identified in these analyses warrant further investigation 
for their utility in the clinical diagnosis of breast cancer.  
 
The results reported herein overall detail the development of novel proteomic workflows as well 
as the identification of both established and novel protein abundance characteristics associated 
with neoplastic progression in breast cancer which will benefit the further development of 
investigating functional biology in proteomic analyses and further will result in expansion of the 
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basic biological understanding of breast cancer as well as which will provide prospective clinical 
tools towards the more facile diagnosis of this disease. 
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